[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 101
1. Kiserud CE, Fosså A, Holte H, Fosså SD: Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer; 2007 May 7;96(9):1442-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-treatment parenthood in Hodgkin's lymphoma survivors.
  • Attempted and achieved post-treatment parenthood, with or without use of assisted reproduction techniques (ARTs), was assessed in Hodgkin's lymphoma survivors treated from 1971-1998, aged below 50 (females) or 65 (males) at diagnosis, aged 18 to 75 at survey.
  • Four treatment groups were constructed: radiotherapy only, low -, medium - and high gonadotoxic chemotherapy (with or without radiotherapy in the three chemotherapy groups).
  • Using Kaplan-Meier estimates, log-rank tests and Cox regression analyses, factors influencing post-treatment parenthood were investigated, with birth of the first child after treatment as the end point.
  • Forty-five per cent (120/269) of males and 50% (91/184) of females reported attempted post-treatment parenthood.
  • In addition 10 males and one female achieved post-treatment parenthood with use of ARTs.
  • Treatment group was significantly associated with post-treatment parenthood, with highest probabilities after radiotherapy only and low gonadotoxic chemotherapy.
  • In univariate analyses, age at diagnosis was a significant factor related to post-treatment parenthood in females.
  • [MeSH-major] Fertility. Hodgkin Disease / physiopathology. Parents

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod Update. 2001 Jul-Aug;7(4):363-9 [11476348.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):779-85 [15963629.001]
  • [Cites] Cytotherapy. 2001;3(4):295-305 [12171718.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1624-9 [12655518.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7555-64 [16234521.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 2;97(21):1580-8 [16264178.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):327-33 [16377179.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):1023-9 [16604098.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2917-31 [16651642.001]
  • [Cites] Hematol Oncol. 2007 Mar;25(1):11-5 [17036376.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv259-65 [15477318.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Am J Med. 1981 Oct;71(4):552-6 [7282743.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):988-93 [6411321.001]
  • [Cites] Arch Toxicol Suppl. 1984;7:140-5 [6083763.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 May;21(5):601-5 [2408897.001]
  • [Cites] Prog Clin Biol Res. 1988;269:481-91 [2839852.001]
  • [Cites] J Clin Oncol. 1990 Feb;8(2):347-55 [2299374.001]
  • [Cites] Haematologica. 1990 Mar-Apr;75(2):155-8 [1694156.001]
  • [Cites] Eur J Cancer. 1991;27(11):1389-92 [1835853.001]
  • [Cites] Hum Reprod. 1992 Nov;7(10):1342-6 [1291557.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):507-12 [8445425.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):387-95 [7844599.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):588-95 [7884420.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):145-50 [8777170.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 8:73-80 [9073051.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(9):873-8 [9613778.001]
  • [Cites] Eur J Cancer. 1997 Dec;33(14):2380-3 [9616285.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):697-709 [10440699.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6587-95 [16170166.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(9):849-57 [11781645.001]
  • (PMID = 17406362.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360165
  •  go-up   go-down


2. Becherer A, Jaeger U, Szabo M, Kletter K: Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med; 2003 Mar;47(1):14-21
Hazardous Substances Data Bank. THALLOUS CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of FDG-PET in malignant lymphoma.
  • Lymphomas have represented an indication for nuclear medicine investigations for 30 years.
  • Gallium-67 scintigraphy has been shown to be a valuable complementary method in Hodgkin's disease and non-Hodgkin lymphoma for detecting viable residual lesions after chemotherapy and for diagnosis of a relapse.
  • Thallium-201 is of interest in differentiating cerebral lymphomas from infectious lesions in AIDS patients but less useful in extra-cerebral lymphomas.
  • PET with fluorine-18-FDG is more accurate than 67Ga in lymphoma.
  • In patients with a positive PET scan after chemotherapy an early relapse occurs in up to 100%, while more than 80% of patients with a negative PET will have a long-term remission.
  • Most studies show that FDG-PET is significantly correlated with patient outcome whereas there is much weaker or even no correlation for CT.
  • The main reason is that PET is not bound to morphological criteria like lymph node size while CT is often not able to differentiate between residual tumour and post-therapeutic fibrosis.
  • Therefore, based on a considerable number of clinical studies, FDG-PET gains increasing significance for staging, restaging and therapy monitoring in malignant lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma / drug therapy. Lymphoma / radionuclide imaging
  • [MeSH-minor] Citrates. Gallium. Hodgkin Disease / radionuclide imaging. Hodgkin Disease / therapy. Indium Radioisotopes. Lymphoma, Non-Hodgkin / radionuclide imaging. Lymphoma, Non-Hodgkin / therapy. Neoplasm Staging / methods. Prognosis. Radiopharmaceuticals. Thallium. Tomography, Emission-Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714950.001).
  • [ISSN] 1125-0135
  • [Journal-full-title] The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
  • [ISO-abbreviation] Q J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Citrates; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 27905-02-8 / gallium citrate; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium; CH46OC8YV4 / Gallium
  • [Number-of-references] 59
  •  go-up   go-down


3. Hodgson DC, Grunfeld E, Gunraj N, Del Giudice L: A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects. Cancer; 2010 Jul 15;116(14):3417-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects.
  • BACKGROUND: The majority of Hodgkin lymphoma (HL) patients are cured, and post-treatment visits are a major component of their management.
  • METHODS: All patients who were diagnosed with HL in Ontario from 1992 through 2000 were identified from a population-based cancer registry.
  • Individual-level linkage with physician claims was used to examine the follow-up care received by 2071 1-year survivors for up to 15 years after their HL diagnosis.
  • Physician visits, imaging studies, and the use of routine and HL-specific cancer screening tests were evaluated.
  • RESULTS: Most patients had visits with both a primary care provider and an oncologist in Years 2 through 5 after their HL diagnosis.
  • In Year 5 after HL diagnosis, 31.8% of patients had at least 1 computed tomography (CT) scan, and 62.9% had a chest x-ray.
  • There were 5352 CT scans performed in Years 2 through 5, and 125 patients subsequently received chemotherapy within 6 months of a CT.
  • Among young women potentially at high risk of breast cancer because of radiation therapy, 87.1% had not received the recommended breast cancer screening.
  • CONCLUSIONS: Radiologic surveillance of HL survivors rarely led to salvage therapy.
  • Despite frequent physician contact, many survivors did not receive established cancer screening interventions, and the recommended early initiation of breast cancer screening among young women at high risk was not widely used.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Quality of Health Care. Survivors
  • [MeSH-minor] Adult. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Office Visits. Ontario. Population Surveillance. Recurrence

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564062.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Bates WD, Gray DW, Dada MA, Chetty R, Gatter KC, Davies DR, Morris PJ: Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol; 2003 Jun;56(6):439-46
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Increased cancer incidence, particularly lymphoproliferative disease, is a complication of immunosuppression in organ transplantation.
  • Non-Hodgkin's lymphomas (NHLs) occur frequently during the first year after transplantation, more so in North America than in Europe.
  • METHODS: This study audited and correlated the demographic, clinical, pathological, and outcome features of post-transplant lymphoproliferative disorders (PTLDs) in a large centre in Oxford, and assessed whether the time of onset fitted more with the European or North American pattern.
  • RESULTS: There were 1383 renal transplants in the study period and 27 patients developed lymphoma: 26 NHLs and one Hodgkin's disease (1.95%).
  • The mean time of diagnosis after transplant was 46 months.
  • Management included reduction of immunosuppression, surgical excision, antiviral treatment, radiotherapy, and chemotherapy.
  • Three patients presented in the first post-transplant year-0.34% of cyclosporin managed patients-similar to the North American incidence, although the incidence of extranodal late PTLDs was also high (mean onset, 36 months v 15 months international mean).
  • Post-transplant lymphomas were the most common malignancy associated with death in transplant patients.
  • CONCLUSIONS: PTLDs occurred in 2% of renal transplant patients, presenting both in the first year in association with cyclosporin use, as in North America, but also in subsequent years, giving an overall presentation time later than the international mean.
  • The disease usually presented extranodally, accounting for the wide range of symptoms and signs.
  • Despite awareness and active management, the disease contributed to death in more that 50% of patients with PTLDs.
  • [MeSH-major] Immunosuppression / adverse effects. Kidney Transplantation. Lymphoma / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclosporine / adverse effects. Female. Humans. Immunosuppressive Agents / adverse effects. Male. Middle Aged. Postoperative Period. Prospective Studies. Registries. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4262-79 [7030473.001]
  • [Cites] Am J Pathol. 1988 Oct;133(1):173-92 [2845789.001]
  • [Cites] Br J Surg. 1989 Oct;76(10):1002-5 [2597939.001]
  • [Cites] Transplant Proc. 1991 Feb;23(1 Pt 2):1101-3 [1899153.001]
  • [Cites] Lancet. 1993 Dec 18-25;342(8886-8887):1514-6 [7902900.001]
  • [Cites] S Afr Med J. 1994 Jan;84(1):16-7 [8197484.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Transplantation. 1995 Jun 27;59(12):1705-9 [7604441.001]
  • [Cites] Lancet. 1995 Aug 12;346(8972):403-6 [7623570.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):8-14 [9044505.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1330-4 [11578286.001]
  • [Cites] Br Med J. 1968 Dec 21;4(5633):746-8 [4881420.001]
  • [Cites] Lancet. 1971 May 15;1(7707):983-6 [4102451.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Transplant Proc. 1985 Apr;17(2):1685-8 [3885506.001]
  • (PMID = 12783971.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  • [Other-IDs] NLM/ PMC1769976
  •  go-up   go-down


5. Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kontopidou FN, Boussiotis VA, Papavassiliou C, Kittas C, Pangalis GA: EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Leuk Lymphoma; 2000 Mar;37(1-2):131-43
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease.
  • To evaluate the efficacy of EBVD combination chemotherapy followed by low dose (LD) involved field (IF) radiation therapy (RT) in patients with clinical stage (CS) I-IIA Hodgkin's disease (HD), we analyzed 148 patients treated in our Unit from March 1988 to November 1995.
  • All drugs were administered i.v. at days 1 and 15, every 4 weeks, for a total of 4-6 cycles.
  • LDIF RT (24-32 Gy) was scheduled for patients with complete response (CR) or >90% reduction of tumor load, after EBVD.
  • Patients with stable or progressive disease (SD, PD) after EBVDx3 or poor compliance to the regimen received mantle or inverted Y RT at standard dose.
  • 129 patients achieved a CR after EBVD and 10 a >90% reduction of tumor load, for a post-CT response rate of 94%.
  • Nine patients relapsed at a median of 7 months from the end of treatment.
  • Six patients have died so far; 5 of HD and one of stroke.
  • One patient developed a diffuse large cell lymphoma 48 months after the diagnosis of HD.
  • We conclude that EBVD followed by LDIF RT is a highly effective regimen for patients with CS I-IIA HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10721777.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; EBVD protocol
  •  go-up   go-down


6. Okuno K, Horie Y, Kanai K, Kato M, Kuwamoto S, Okazaki T, Hayashi K: Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia. J Clin Exp Hematop; 2009 May;49(1):45-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia.
  • Post-transplant lymphoproliferative disorder (PTLD) is one of the most important complications of solid organ transplantation or hematopoietic stem cell transplantation.
  • Although post-transplant Hodgkin lymphoma (HL) is included in PTLD, there have been no studies in the literature on adult cases of post-transplant HL after cord blood stem cell transplantation (CBSCT).
  • This is due to the fact that EBV infection of cord blood cells usually does not occur, and EBV-infected lymphocytes of the recipient should be eradicated by preconditioning therapy.
  • We report a 26-year-old woman case of post-transplant HL, which occurred after CBSCT for relapsed acute lymphoblastic leukemia.
  • Three years and eight months after CBSCT, the enlarged cervical lymph node was histologically diagnosed as EBV associated post-transplant HL, which showed immunophenotypes of classical HL and latency type II EBV infection.
  • She underwent chemotherapy, and has survived 4 years and 6 months after CBSCT.
  • Differential diagnosis of post-transplant HL with good prognosis and HL-like PTLD with aggressive behavior is important, and immunohistochemical methods were useful and essential for it.
  • The source of EBV associated HL in this case will be discussed.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Hodgkin Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Diagnosis, Differential. Epstein-Barr Virus Infections / etiology. Female. Herpesvirus 4, Human. Humans. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Treatment Outcome. Young Adult


7. Castellani MR, Cefalo G, Terenziani M, Aliberti G, Maccauro M, Alessi A, Villano C, Bombardieri E: Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value. Q J Nucl Med; 2003 Mar;47(1):22-30
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.
  • AIM: The aim of the present paper is to describe the accuracy of gallium ((67)Ga) scintigraphy in adolescents and children with Hodgkin's disease (HD).
  • We have studied the diagnostic value of this nuclear imaging technique at disease presentation (staging) and its prognostic value based on changes in (67)Ga uptake observed after treatment (response assessment).
  • METHODS: From April 1985 to July 1999 74 consecutive untreated patients with a median age of 13 y underwent (67)Ga scans 48-72 h after injection of 37-111 MBq of (67)Ga-citrate.
  • Planar whole-body scintigraphy was performed, supplemented with single photon emission tomography (SPET) of the mediastinum from 1996 onwards.
  • Three patients did not undergo further scintigraphic examination because they were treated with radical surgery.
  • After the 1st examination 71 of the 74 patients were monitored by 1-3 (67)Ga scans during the course of their disease.
  • All of them had at least one (67)Ga scintigraphy at the end of the induction phase of chemotherapy, before any other therapeutic regimens were planned.
  • RESULTS: At disease presentation (67)Ga scintigraphy was positive in all patients, detecting 285 of 335 (85.0%) lymph nodal sites of disease.
  • Among 71 patients in follow-up, 2 showed rapid progression of disease during induction therapy while 69 patients were monitored for a long period.
  • The response to therapy has been classified according to the changes observed on nuclear medicine or radiological images as complete response (CR) or partial response (PR).
  • PR or progression was found with (67)Ga scintigraphy in 16 patients (22.5%) and with radiological modalities in 42 patients (59.1%). (67)Ga scan was concordant with clinical outcome in 97% (28/29).
  • The diagnostic effectiveness of this imaging technique has been analysed by comparing the scintigraphic or radiological changes at the 1st scintigraphic/radiological follow-up examination after induction therapy with the clinical outcome.
  • In this population the relapse rate was 50% (8/16) in the group that did not achieve a CR according to post-treatment (67)Ga scintigraphy, while it was only 10.9% (6/55) in the group that achieved a CR on the basis of scintigraphy findings.
  • The overall survival (OS) and disease-free survival (DFS) were calculated by means of Kaplan-Meier cumulative survival plotting.
  • When the 2 groups of patients with complete (CR) or incomplete normalisation (PR or progression) of (67)Ga scintigraphy were compared, both OS and DFS were found to be statistically different (p=0.0001 and p=0.0004, respectively).
  • On the basis of X-ray results the relapse rate was 13.7% in patients with negative post-therapy findings and 23.8% in patients with positive radiological imaging.
  • CONCLUSION: Our data demonstrate the high value of (67)Ga scintigraphy in HD staging in paediatric patients.
  • In addition, evaluation of the (67)Ga uptake is very useful as a prognostic parameter; changes in (67)Ga uptake after therapy indicate a favourable prognosis, whereas children still positive on post-treatment (67)Ga scintigrams should be given more aggressive treatment.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / radionuclide imaging. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Follow-Up Studies. Humans. Neoplasm Staging / methods. Prognosis. Radiopharmaceuticals. Retrospective Studies. Single-Blind Method. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714951.001).
  • [ISSN] 1125-0135
  • [Journal-full-title] The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
  • [ISO-abbreviation] Q J Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


8. Jenkins BD, Snower D, Mohamed A, Al-Katib A: Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma. Am J Hematol; 2005 Jun;79(2):128-31
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma.
  • A 41-year-old Caucasian female was diagnosed with a CD3(+) CD4(+) CD8(+) variant of lymphoproliferative disorder of granular lymphocytes (LDGL) in the third year of remission following treatment of stage III-B Hodgkin lymphoma (HL).
  • The patient was asymptomatic at diagnosis, without clinical evidence of immune disorder or recurrence of HL.
  • Diagnosis was made incidentally, secondary to lymphocytosis discovered on a routine follow-up post HL therapy.
  • Clonal chromosomal abnormalities were seen in 20% of peripheral blood lymphocytes with a karyotype 46, XX, t(2;6;2;11) (p13;q23;q24;q23).
  • The breakpoint on 11q23 is distal to the MLL gene as shown by fluorescence in situ hybridization (FISH) analysis.
  • To our knowledge, this is the first report of variant LDGL in association with HL treatment with documented clonal chromosomal abnormalities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bleomycin / adverse effects. Dacarbazine / adverse effects. Doxorubicin / adverse effects. Granulocytes / pathology. Hodgkin Disease / drug therapy. Lymphoproliferative Disorders / blood. Lymphoproliferative Disorders / chemically induced. T-Lymphocytes / pathology. Vinblastine / adverse effects
  • [MeSH-minor] Adult. Antigens, CD3 / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / pathology. Chromosome Aberrations. Cytogenetic Analysis. Female. Humans. Lymphocytosis / chemically induced. Lymphocytosis / pathology. Neoplasm Staging. Phenotype

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929104.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


9. Di Cesare E, Cerone G, Enrici RM, Tombolini V, Anselmo P, Masciocchi C: MRI characterization of residual mediastinal masses in Hodgkin's disease: long-term follow-up. Magn Reson Imaging; 2004 Jan;22(1):31-8
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI characterization of residual mediastinal masses in Hodgkin's disease: long-term follow-up.
  • Our purpose was to evaluate the role of MRI in distinguishing fibrous from active residual masses in treated Hodgkin's disease.
  • Forty patients with residual mediastinal mass larger than 1.5 cm underwent MRI 1, 3, 6, and 12 months after the end of cycles of prescribed chemotherapy or combined chemoradiotherapy.
  • Each time the residual mass was evaluated in size and signal intensity on spin echo (SE) T(2)-weighted images and on SE T(1)-weighted images after contrast medium.
  • Low signal intensity and low contrast enhancement were considered signs of inactive residues; homogeneous high signal intensity and high contrast enhancement were indicative of active residual disease; heterogeneous signal intensity and heterogeneous contrast enhancement were indicative of partial remission or necrotic/inflammatory phenomena.
  • MR showed high diagnostic accuracy in the evaluation of Hodgkin's mediastinal residues after treatment, if performed at least 6 months after the end of therapy, reaching the highest sensitivity and specificity values at 12 month follow-up (considering the three parameters-T(2) signal intensity, contrast-enhancement, and size-all together).
  • MR diagnostic accuracy at the 6-month follow-up was lower due to the higher incidence of inhomogeneous pattern.
  • The accuracy of MR performed at 1 and at 3 months after the end of therapy was not satisfying.
  • This represents a clinical problem because the most important clinical decisions have to be taken just in this early post-treatment phase.
  • [MeSH-major] Hodgkin Disease / pathology. Magnetic Resonance Imaging / methods. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Contrast Media. Female. Follow-Up Studies. Gadolinium DTPA. Humans. Longitudinal Studies. Male. Neoplasm, Residual. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14972392.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


10. Zebrack BJ, Zeltzer LK, Whitton J, Mertens AC, Odom L, Berkow R, Robison LL: Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study. Pediatrics; 2002 Jul;110(1 Pt 1):42-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study.
  • OBJECTIVE: To evaluate and compare psychological outcomes in long-term survivors of pediatric leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma and sibling controls.
  • METHODS: Adult survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma (N = 5736) and sibling controls (N = 2565) were administered a long-term follow-up questionnaire allowing assessment of symptoms associated with depression and somatic distress.
  • RESULTS: The majority of respondents in this study did not demonstrate symptomatology indicative of depression or somatic distress.
  • Women were significantly more likely to indicate symptoms of depression and somatic distress than were men; however, this difference did not vary by survivor/sibling status.
  • Similarly, socioeconomic (SES) variables predicted symptomatic levels of depression and somatic distress for both survivors and siblings, and these effects did not vary by survivor/sibling status.
  • Among leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma survivors, in addition to gender and SES, the only treatment variable that predicted scores indicating depressive symptomatology was exposure to intensive chemotherapy.
  • Exposure to intensive chemotherapy also predicted scores indicative of somatic distress symptoms.
  • No other medical variables, including diagnostic category, age at diagnosis, time since diagnosis, and duration of treatment, predicted symptomatic scores for depression and somatic distress.
  • CONCLUSIONS: This large, sibling-controlled, multisite study of young adult survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma found that survivors had significant increased risk for reporting symptoms of depression and somatic distress and that intensive chemotherapy added to this risk.
  • However, being a cancer survivor did not compound the effects of gender and SES variables on the 2 outcomes measured.
  • The ability of SES, gender, and treatment-related variables to predict psychological symptoms in this cohort of childhood survivors and sibling controls calls for future research into varied biological and psychosocial pathways by which cancer influences future psychosocial functioning.
  • [MeSH-major] Depressive Disorder / diagnosis. Hodgkin Disease / psychology. Leukemia / psychology. Lymphoma, Non-Hodgkin / psychology. Somatoform Disorders / diagnosis. Survivors / psychology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Attitude to Health. Child. Family. Female. Health Status. Humans. Male. Multivariate Analysis. Outcome Assessment (Health Care). Prevalence. Sex Factors. Stress Disorders, Post-Traumatic / diagnosis. Stress Disorders, Post-Traumatic / epidemiology. Stress, Psychological / diagnosis. Stress, Psychological / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatrics. 2003 Dec;112(6 Pt 1):1454-5; author reply 1454-5 [14654630.001]
  • (PMID = 12093945.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / F32CA89875-01; United States / NCI NIH HHS / CA / U24 CA55727
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


11. Manojkumar R, Sharma A, Grover A: Secondary lymphoma of the heart presenting as recurrent syncope. Indian Heart J; 2001 Mar-Apr;53(2):221-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary lymphoma of the heart presenting as recurrent syncope.
  • Transthoracic echocardiogram revealed a homogeneous tumor mass in the right ventricular cavity with extension into the outflow region.
  • Left cervical lymph node biopsy confirmed the diagnosis of non-Hodgkin's lymphoma.
  • The tumor resolved completely with chemotherapy without surgical intervention.
  • [MeSH-major] Heart Neoplasms / complications. Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Syncope / etiology
  • [MeSH-minor] Amiodarone / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Child. Cyclophosphamide. Doxorubicin. Echocardiography, Transesophageal. Electrocardiography. Follow-Up Studies. Humans. Male. Prednisolone. Recurrence. Tachycardia, Ventricular / etiology. Tomography, X-Ray Computed. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - Fainting.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11428484.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; N3RQ532IUT / Amiodarone; VAP-cyclo protocol
  •  go-up   go-down


12. Ziora K, Bubała H, Głowacki J, Sońta-Jakimczyk D, Legaszewski T, Zajecki W: [Thyroid function after external irradiation of the neck in patients with Hodgkin's disease--long-term observation]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006;12(4):261-7
MedlinePlus Health Information. consumer health - Thyroid Tests.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid function after external irradiation of the neck in patients with Hodgkin's disease--long-term observation].
  • [Transliterated title] Czynność tarczycy po radioterapii okolicy szyi u pacjentów z choroba Hodgkina--długoletnia obserwacja.
  • INTRODUCTION: The modern therapy of Hodgkin's disease (HD): chemotherapy (CT) or/and radiotherapy (RT) gives a chance of a long time survival but it brings a possibility of early and late complications including thyroid gland function disorders (post-radiotherapy thyroiditis, thyroid hypofunction, Graves disease, thyroid nodules, thyroid cancer).
  • AIM: Evaluation of thyroid gland function in patients with total HD remission status from 6 to 16 years after the treatment.
  • MATERIAL AND METHODS: The study included 29 patients suffering from HD (9 women, 20 men, mean age 22.8 years), treated with CT (cycles MVPP and B-DOPA) and with RT (cervical region; 18-40 Gy) in their childhood.
  • The thyroid gland on the average 6 (1st examination) and 16 years (2nd examination) after the treatment as well as thyroid hormones (TSH, fT3, fT4), thyroglobulin (Tg) and anti-thyroid antibodies in blood serum were estimated.
  • RESULTS: There were no abnormalities in thyroid palpation examination in any patient.
  • In 8 patients thyroid nodules were found, in one thyroid papillary carcinoma was diagnosed.
  • In one patient (3.4%) the features of subclinical thyroid hypofunction and in 17.2% the increased level of Tg in blood serum with normal thyroid hormone levels were found.
  • In two patients (6.8%) the raised titre of a-TG and a-TPO was observed.
  • In majority of patients with HD after RT in cervical region in long term remission period the normal thyroid function was observed.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Hodgkin Disease / radiotherapy. Neck / radiation effects. Radiotherapy, Adjuvant / adverse effects. Thyroid Function Tests. Thyroid Gland / radiation effects. Thyroid Hormones / blood
  • [MeSH-minor] Adolescent. Adult. Biopsy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / etiology. Child. Female. Follow-Up Studies. Humans. Longitudinal Studies. Male. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Radiation-Induced / etiology. Poland. Radiation Injuries / etiology. Retrospective Studies. Thyroid Nodule / diagnosis. Thyroid Nodule / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239303.001).
  • [ISSN] 1234-625X
  • [Journal-full-title] Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologów Dziecięcych
  • [ISO-abbreviation] Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Thyroid Hormones
  •  go-up   go-down


13. Wooldridge JE, Link BK: Post-treatment surveillance of patients with lymphoma treated with curative intent. Semin Oncol; 2003 Jun;30(3):375-81
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-treatment surveillance of patients with lymphoma treated with curative intent.
  • Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma (NHL) are common, potentially curable cancers.
  • Despite modern therapy, many patients will relapse.
  • A number of relapsing patients may be cured with subsequent treatment, including high-dose chemotherapy.
  • Risk of relapse after potentially curative therapy is greatest in the first 2 years, and post-treatment surveillance should be concentrated during this time.
  • [MeSH-major] Continuity of Patient Care / standards. Lymphoma / diagnosis. Mass Screening / standards. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Clinical Laboratory Techniques. Diagnostic Imaging. Humans. Practice Guidelines as Topic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12870139.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


14. Lerner RE, Weisdorf DJ, Miller JS, McGlave PB, Burns LJ: The international prognostic index at relapse predicts autologous stem cell transplantation outcome for aggressive non-Hodgkin's lymphoma in second remission or chemosensitive first relapse. J Clin Oncol; 2004 Jul 15;22(14_suppl):6661

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The international prognostic index at relapse predicts autologous stem cell transplantation outcome for aggressive non-Hodgkin's lymphoma in second remission or chemosensitive first relapse.
  • : 6661 Background: Autologous stem cell transplantation (ASCT) has become the standard treatment for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) responding to conventional salvage chemotherapy.
  • The international prognostic index (IPI) was developed to identify patients with aggressive NHL who have different risks for death.
  • The objective of the present study was to investigate the prognostic value of the IPI at relapse for patients with aggressive NHL undergoing ASCT.
  • Clinical features predictive of overall survival (OS) and progression-free survival (PFS) were analyzed.
  • RESULTS: Post ASCT, CR was achieved in 73 patients (91%).
  • With a median follow-up of 5 years (range 205 days to 14 years), OS and PFS at 5 years were 37% (95% CI 26-48) and 37% (95% CI 26-48), respectively.
  • The high-risk group (3, 4, or 5 IPI factors) had 3.2 times (95% CI 1.5-6.6, p = .002) the risk of death and 3.5 times (95% CI 1.6-7.3, p = .001) the risk of relapse as the low-risk group (0, 1, or 2 IPI factors).
  • In Cox regression analysis, high-risk IPI status (RR 3.8, 95% CI 1.7-8.4, p = .001) and bone marrow (BM) involvement at diagnosis (RR 2.9, 95% CI 1.3 - 6.3, p = .009) were independent predictors for poor OS.
  • Patients with high-risk IPI status at relapse should be considered for novel therapeutic approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016372.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bowers DC, McNeil DE, Liu Y, Yasui Y, Stoval M, Gurney JG, Hudson MM, Robison LL, Oeffinger KC, Childhood Cancer Survivors Study: Stroke following therapy for Hodgkin's Disease (HD): A report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol; 2004 Jul 15;22(14_suppl):8523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stroke following therapy for Hodgkin's Disease (HD): A report from the Childhood Cancer Survivor Study (CCSS).
  • : 8523 Background: An increased risk for strokes has not been previously reported among HD survivors.
  • This report examines the rate and risk factors for stroke in long-term survivors of HD.
  • METHODS: The CCSS is a multi-institutional cohort study of long-term (≥ 5 years) survivors who were diagnosed between 1970-1986.
  • The rate of first occurrence of self-reported strokes was determined for HD survivors (N=1665) and compared with a random sample of siblings of childhood cancer survivors (N=3846).
  • The mean age at interview of the HD survivors was 31.9 years of age, with a mean age at diagnosis of 14.6 years.
  • The incidence rates of HD survivors at ≥ 5 years post diagnosis and siblings were calculated separately.
  • Cox proportional hazards models were used to estimate rate ratio (RR) of developing stroke between HD survivals and siblings.
  • RESULTS: Fifteen HD survivors reported a stroke: one during therapy, 13 occurring ≥ 5 years after HD diagnosis, and one without an age at stroke reported.
  • The rate of stroke in HD survivors ≥ 5 years post diagnosis was 0.68 per 1000 person-years (95% CI, 0.40-1.18).
  • Of the 13 late occurring strokes, all had chest/mantle radiation (median dose 40 Gy), with a median interval of 15 years from HD diagnosis to stroke.
  • Seven siblings reported a previous stroke, with a rate of 0.069 per 1000 person-years (95% CI, 0.03-0.15).
  • The RR of stroke for all HD survivors, in comparison with siblings, was 3.88 (95% CI, 1.46-10.3; p = 0.0065).
  • The rate of stroke for HD survivors who were treated with chest radiation therapy (RT) was 0.82 per 1000 person-years (95% CI, 0.48-1.41).
  • Compared to siblings, the RR of HD survivors treated with chest RT was 4.28 (95% CI, 1.6-11.2; p=0.0031).
  • Anthracycline exposure, treatment with chemotherapy only, hypertension and diabetes mellitus were not associated with an increased risk of stroke.
  • CONCLUSIONS: Though an infrequent outcome, survivors of childhood HD may be at an increased risk of stroke.
  • In this study, previous exposure to chest RT was strongly associated with risk of stroke.
  • Because the risk may be modified by prevention, it is imperative to further study this process.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Reategui RD, Beltran B, Morales D, Vera L, Quinones P, Portugal K, Desposorio C, Capellino A, Castillo J: AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru. J Clin Oncol; 2009 May 20;27(15_suppl):e19545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru.
  • The impact of HAART on the survival of ARL in developing countries in the post-HAART era has not been clearly defined.
  • The aims of this study were to evaluate efficacy of HAART on survival and prognostic factors in our population.
  • METHODS: The clinical records of 2,502 HIV-infected patients seen in our institution from March 1997 to March 2008 were reviewed.
  • RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.
  • From the 48 ARL identified 44 were non Hodgkin lymphoma (NHL) and 4 were Hodgkin lymphoma.
  • From 42 systemic NHL: 38 (90,5%) were of B-cell and 4 (9,5%) were of T-cell.
  • Three groups of patients were included: 13 patients (31%) received HAART previous the diagnosis of ARL, 21 patients (50%) initiated HAART after ARL diagnosis and 8 patients (19%) did not receive HAART.
  • HAART treatment before the diagnosis of NHL increases the survival (54% versus 9,5% versus 25% respectively, p=0.048).
  • Twenty of 42 patients (47,6%) received chemotherapy.
  • This group had a better survival rate than those who did not receive chemotherapy (50% versus 4,5%, p< 0.0001) The overall response to chemotherapy was 80% with CR (n=11, 55%), PR(n=5, 25%) and PD in four (20%).
  • In a multivariate analysis, IPI score > 2, presence of B symptoms and no HAART previous ARL diagnosis were statistically associated to worse survival with p-values of 0.0001, 0.018 and 0.048 respectively.
  • CONCLUSIONS: In our study the use of HAART is effective when started before ARL diagnosis.
  • IPI score > 2, B symptoms and no HAART previous the diagnosis were unfavorable prognostic factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Torre V, Cavallari V, Bucolo S, Abbate G, Romano G, Fera G, Galletti B: [Description of a particular case of the so-called Schmincke lymphoepithelioma and study of the correlation with Epstein-Barr virus]. Acta Otorhinolaryngol Ital; 2000 Oct;20(5):347-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Description of a particular case of the so-called Schmincke lymphoepithelioma and study of the correlation with Epstein-Barr virus].
  • [Transliterated title] Descrizione di un caso particolare del cosiddetto linfoepitelioma di schmincke e studio delle correlazioni con il virus di Epstein-Barr.
  • For poorly differentiated rhinopharyngeal carcinomas, the clinical presentation (association with the Epstein-Barr virus, paraneoplastic syndromes, onset of lymphoma) and the histopathological features can be polymorphous and they can confound or delay diagnosis and preparation of an adequate treatment plan (radio-chemotherapy).
  • Often these neoplasms arise as clinically primitive laterocervical metastases, masked by clinical findings and a history that can lead to the mistaken diagnosis of systemic lymphoproliferative processes such as Hodgkin's disease.
  • Here an observation of this type is presented in a young patient (19 years old) who came under observation for a laterocervical tumefaction recurrent from a previous exeresis performed at another hospital and symptoms of serotine febricula, dysphagia and serology positive for the Epstein-Barr virus (EBV).
  • The patient underwent surgery and then radiotherapy and has been under close post-operative follow-up for two years.
  • To date the patient's condition--both local and general--is good.
  • The particular histology of the neoformation lies in the abundant infiltration of plasma cell and lymphocyte eosinophils, at times in blastic form.
  • Moreover, elements with a large clear nucleus and evident nucleolus (Hodgkin-like) and scattered multinucleate Langhans-type giant cells can be seen.
  • Immunohistologically the tumor cells markedly express for cytokeratin and the latent membrane protein (LMP1) of the Epstein-Barr virus (EBV) and show a high growth fraction.
  • Under the electron microscope, the plurinucleate giant cells present large nuclei with morphology similar to that of tumor cells.
  • The clear cytokeratin-positivity of the tumor elements and the histological and ultrastructural features mentioned led to the diagnosis of a massive metastasis from lymphoepithelial carcinoma, the Schmincke variant, plus EBV infection of the neoplastic cells.
  • The authors conclude assuming that the particular granulomatous reaction is due to the host's reaction to the tumor cells, but also to the reaction to the viral antigens.
  • In the former case we find an attempt to limit the carcinomatous process; in the latter it is a response caused by the EBV and is not, apparently, aimed at protecting against the neoplasm rather it facilitates the neoplastic process.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284263.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Dienstbier Z, Skala E, Blomannová E: [Clinical study of Hodgkin's disease after 25 years]. Cas Lek Cesk; 2004;143(3):184-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of Hodgkin's disease after 25 years].
  • [Transliterated title] Klinická studie MORbus HOdgkin po 25 letech.
  • BACKGROUND: On the 25th anniversary of the unified protocol of 1978, the authors report the results of the first clinical study in the Czech Republic performed in patients with Hodgkin's lymphoma.
  • 290 patients were treated with both chemotherapy (Cyklophosphamide, Natulan, Prednison, Vinblastin) and radiotherapy according to this widely used protocol.
  • The dosage of cytotoxic therapy was reduced based on age, in patients over 50 years of age.
  • Of the 66 (22.8%) patients that died, the cause of death in 33 patients was Hodgkin's lymphoma.
  • In one case, phocomelia was diagnosed post-partum.
  • In this instance, no causal relationship to the cytotoxic treatment (which had been given three years before the birth) could be established.
  • In one case, a possible genetic relationship was noted--both the father and the daughter suffered from Hodgkin lymphoma and the granddaughter from non-Hodgkin lymphoma.
  • CONCLUSIONS: The success of this treatment depends on complex diagnostic procedures, and on an experienced team of physicians.
  • [MeSH-major] Hodgkin Disease / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15134038.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


19. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL: A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant; 2005 Mar;35(6):557-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
  • There are several prognostic models for Hodgkin's disease (HD) patients, but none evaluating patient characteristics at time of blood and marrow transplantation (BMT).
  • We developed a prognostic model for event-free survival (EFS) post-BMT based on HD patient characteristics measured at the time of autologous (auto) or allogeneic (allo) BMT.
  • Between 1/1991 and 12/2001, 64 relapsed or refractory HD patients received an auto (n=46) or allo (n=18) BMT.
  • A multivariate prognostic model was developed measuring time to relapse, progression or death.
  • Significant multivariate predictors of shorter EFS were chemotherapy-resistant disease, KPS <90 and > or =3 chemotherapy regimens pre-BMT.
  • We were able to differentiate patients at high vs low risk for adverse outcomes post-BMT.
  • This prognostic model may prove useful in predicting patient outcomes and identifying high-risk patients for novel treatment strategies.
  • Validation of this model in a larger cohort of patients is warranted.
  • [MeSH-major] Bone Marrow Transplantation. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Peripheral Blood Stem Cell Transplantation. Prognosis
  • [MeSH-minor] Adult. Cause of Death. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Graft Survival. Humans. Male. Middle Aged. Models, Theoretical. Multivariate Analysis. Salvage Therapy. Survival Analysis. Time. Transplantation, Autologous. Transplantation, Homologous


20. Amini RM, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Glimelius B: Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. Eur J Haematol; 2000 Dec;65(6):379-89
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience.
  • BACKGROUND: Despite improved treatment results achieved in Hodgkin's disease (HD), only about 70% of patients with advanced stages are cured.
  • The primary aim of this study was to evaluate the outcome of advanced stages (IIB-IVB) of HD in younger patients in an unselected population-based group of patients.
  • The patients were recommended individualized treatment with respect to number of chemotherapy (CT) courses and post-CT radiotherapy (RT) based on pretreatment characteristics and tumour response.
  • PATIENTS AND METHODS: Between 1985-92, 307 patients between 17-59 yr of age (median 36) were diagnosed with HD in stages IIB-IVB in 5/6 health care regions in Sweden.
  • Median follow-up time was 7.8 yr (1.3-13).
  • The overall and disease-free 10-yr survivals in the whole cohort were 76% and 67%, respectively.
  • Survival was not higher for patients in CR after CT when RT was added.
  • For those in PR after CT, additional RT raised the frequencies of CR.
  • A selected group of pathologically staged patients was successfully treated with a short course (2 cycles) of CT + RT.
  • In univariate analyses survival was affected by age, stage IVB, bone-marrow involvement, B-symptoms, S-LDH, S-Alb and reaching CR or not after 2, 4 and 6 cycles of CT.
  • In a multivariate analysis, age and reaching CR after 6 cycles of CT remained statistically significant.
  • CONCLUSIONS: The lack of difference in survival between the groups of patients who received 6 versus 8 cycles of CT indicates a successful selection of patients for the shorter treatment.
  • Whether some patients need less CT than the generally recommended 8 courses can properly only be evaluated in a randomised study.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Antineoplastic Agents / therapeutic use. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. National Health Programs. Neoplasm Staging. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Risk Factors. Survival Rate. Sweden / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11168495.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Fohrer C, Oprea C, Herbrecht R: [Post-therapy surveillance in non-Hodgkin's lymphomas]. Rev Prat; 2002 May 1;52(9):986-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-therapy surveillance in non-Hodgkin's lymphomas].
  • [Transliterated title] Surveillance post-thérapeutique des lymphomes non hodgkiniens.
  • Post-treatment surveillance in non-Hodgkin's lymphoma is required for an early diagnosis of a relapse and for the detection of a potential late treatment-related complication.
  • The risk of relapse is highest during the first 2 years in aggressive lymphomas.
  • For low-grade lymphomas, the relapse rate remains constant for a longer period and late relapses are more common.
  • Clinical examination and biological tests (blood cell count, lactate dehydrogenase and, in some instance, beta-2-microglobulin serum level determination) are the basis of the surveillance.
  • The frequency of the surveillance mainly depends on the histological subtype.
  • Late chemotherapy-related complications include second cancer (solid tumor, myelodysplastic syndrome and acute leukemia), cardiac and endocrine toxicity.
  • Detection of these events also requires close clinical and biological monitoring.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematologic Tests. Humans. Physical Examination. Prognosis. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063766.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 26
  •  go-up   go-down


22. Rohr JC, Wagner HJ, Lauten M, Wacker HH, Jüttner E, Hanke C, Pohl M, Niemeyer CM: Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant; 2008 Jun;12(4):426-31
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.
  • The development of lymphomas after SOT is a well-known complication of the immunosuppressive therapy necessary to prevent graft rejection.
  • Epstein-Barr virus plays a central role in the pathogenesis of lymphomas because of its ability to transform infected cells.
  • Differentiating PTLD from malignant lymphomas, especially HL can be challenging.
  • We report on two patients, who developed EBV-associated lymphomas several years after SOT.
  • A histological examination of lymph nodes led to a diagnosis of HL in both patients, who were started on chemotherapy according to current treatment protocols.
  • A rapid and complete remission in one patient prompted us to analyze the expression pattern of EBV-latency genes.
  • In this patient, the EBV expression profile revealed a latency type III suggesting the diagnosis of Hodgkin-like PTLD.
  • The other patient required six courses of chemotherapy plus radiotherapy to reach a complete remission.
  • In his tumor cells, a restricted EBV-latency type II pattern was found, suggesting a diagnosis of classical HL.
  • These two cases demonstrate that in post-transplant lymphomas with histological features of HL, an analysis of the expression pattern of EBV proteins might aid in the differentiation between PTLD and HL.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / metabolism. Hodgkin Disease / etiology. Hodgkin Disease / virology. Kidney Transplantation / adverse effects. Liver Transplantation / adverse effects. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / virology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Cyclosporine / adverse effects. Diagnosis, Differential. Humans. Immunosuppressive Agents / adverse effects. Lymph Nodes / pathology. Male


23. Smit M, van Casteren NJ, Wildhagen MF, Romijn JC, Dohle GR: Sperm DNA integrity in cancer patients before and after cytotoxic treatment. Hum Reprod; 2010 Aug;25(8):1877-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm DNA integrity in cancer patients before and after cytotoxic treatment.
  • BACKGROUND: We assessed sperm DNA fragmentation index (DFI) in cancer patients before and after treatment to evaluate if sperm DNA integrity is compromised by cancer itself or its treatment.
  • METHODS: In a prospective study, DFI was assessed in 127 patients diagnosed with testicular germ cell tumours (TGCT), Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL) and various malignancies.
  • The severity of cancer and tumour markers at diagnosis was recorded.
  • Follow-up DFI after treatment was available in 52 patients who were mostly less severely affected.
  • RESULTS: In patients diagnosed with TGCT, HL and various malignancies, pretreatment DFI levels were not significantly different from that of proven fertile controls, but in patients with NHL an increased DFI was found.
  • An overall significant decrease in post-treatment DFI (13.2% range 5.0-70.5) compared with pretreatment values (17.1% range 5.1-66.6) was found (P = 0.040).
  • In TGCT patients, post-treatment DFI was significantly higher in patients who were treated with radiotherapy (16.9% range 11.5-39.9) compared with that in patients treated with chemotherapy (CT) alone (10.9% range 5.5-39.9) (P = 0.037).
  • In HL patients, the type of treatment or number of CT cycles was not associated with DFI.
  • Overall, post-treatment DFI in cancer patients was not significantly different from that of proven fertile controls.
  • CONCLUSIONS: In this study, the presence of cancer does not seem to negatively affect the sperm DNA integrity in TGCT and HL patients; only NHL patients showed increased DFI at the time of diagnosis compared with healthy controls.
  • Our results confirm previous reports that DFI decreases significantly following various anti-cancer treatments.
  • In contrast, radiotherapy in TGCT patients is associated with an increase in DFI compared with CT treatment alone.
  • [MeSH-major] Antineoplastic Agents / adverse effects. DNA Fragmentation. Spermatozoa / drug effects
  • [MeSH-minor] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Male. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / radiotherapy. Semen Analysis. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2011 Apr;185(4):1405 [22098987.001]
  • (PMID = 20551071.001).
  • [ISSN] 1460-2350
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Bachmeyer C, Henni MA, Blanc AS, Langman B, Kazerouni F, Cadranel JF: [Chylous ascitis revealing a non-Hodgkin lymphoma]. Presse Med; 2004 Feb 14;33(3):167-9
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chylous ascitis revealing a non-Hodgkin lymphoma].
  • [Transliterated title] Ascite chyleuse révélatrice d'un lymphome non hodgkinien.
  • It is due to an interruption in the lymphatic system due either to an obstruction or to a post-traumatic wound.
  • We report a case of revealing a non-Hodgkin lymphoma.
  • The diagnosis of grade IV (Ann Arbor classification) centro-follicular non-Hodgkin lymphoma was retained.
  • The ascitis disappeared following chemotherapy.
  • COMMENTS: Chylous ascitis is an uncommon complication of lymphomas, although representing the main cause in adults in developed countries.
  • CONCLUSION: Chylous ascitis is a rare complication of lymphomas, secondary to the obstruction of the abdominal draining lymphatics.
  • Treatment is the same as that of a hematologic malignancy.
  • [MeSH-major] Chylous Ascites / etiology. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Radiography, Abdominal. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15029028.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


25. Centkowski P, Sawczuk-Chabin J, Prochorec M, Warzocha K: Hodgkin's lymphoma and tuberculosis coexistence in cervical lymph nodes. Leuk Lymphoma; 2005 Mar;46(3):471-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma and tuberculosis coexistence in cervical lymph nodes.
  • We describe the case of a 47-year-old man admitted to the Department of Hematology because of fever, enlarged cervical and supraclavicular lymph nodes, hepatosplenomegaly and non-specific lung infiltrations.
  • The histopathological examination of the cervical lymph node revealed Hodgkin's lymphoma (HL) NS type I.
  • Clinical evaluation revealed stage IVB according to Ann Arbor classification and the presence of 5 unfavorable prognostic factors according to the International Prognostic Index.
  • Despite BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), the enlarged lymph nodes, lung infiltrations and fever persisted.
  • Microbiological and serological tests did not lead to the identification of any viral or bacterial pathogens.
  • Bronchoscopy showed chronic inflammation and post-tuberculosis (TB) scars in bronchi without acid-fast bacilli in bronchoalveolar lavage (BAL) in culture and polymerase chain reaction (PCR) tests.
  • The auramin staining presented acid-fast bacilli and allowed the diagnosis of productive and caseating TB coexisting with HL.
  • The 4 tuberculostatics regimen and ABVD chemotherapy (adriamycin, bleomycin, vincristine, dacarbazine) resulted in a complete clinical response after 3 months of treatment.
  • In conclusion, the association between HL and TB must be considered, especially in countries where the latter is endemic.
  • The diagnosis may be difficult due to similarities in the clinical course, laboratory tests and imaging procedures.
  • [MeSH-major] Hodgkin Disease / complications. Lymph Nodes / pathology. Tuberculosis, Lymph Node / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antitubercular Agents / therapeutic use. Humans. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621842.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


26. Iagaru A, Wang Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS: (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Hell J Nucl Med; 2008 Sep-Dec;11(3):153-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
  • Assessing the response to treatment as soon after treatment initiation is one of the key reasons for imaging lymphoma patients.
  • The optimal time after initiating treatment for assessing response to treatment has yet to be determined.
  • Therefore, we were prompted to review our experience with serial (18)F-FDG PET/CT in patients undergoing treatment for Hodgkin's disease (HD) and non Hodgkin's lymphoma (NHL).
  • This is a retrospective study (Feb 2003 - Oct 2004) of 20 patients, 11 men and 9 women, with age range of 7-75 years with diagnosis of HD (10) and NHL (10), who had PET/CT at our institution prior, during and at the completion of therapy.
  • Restaging PET/CT was done after 2 cycles of chemotherapy in 10 patients (group A) and after 4 cycles of chemotherapy in 10 pts (group B).
  • This had no statistical significance (P value: 0.31).
  • The DeltaSUV from baseline to post-therapy PET/CT was on average 72.9% in group A and 79.8% in group B.
  • This difference also had no statistical significance (P value: 0.24).
  • Results of PET/CT after 2 cycles of chemotherapy did not statistically differ from the results of PET/CT after 4 cycles of chemotherapy.
  • [MeSH-major] Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081857.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


27. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI: Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep; 2010 Nov;12(6):383-94
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
  • Post-transplantation lymphoproliferative disorders (PTLD) are a heterogenous group of abnormal lymphoid proliferations that occur after solid organ transplant (SOT) or hematopoietic transplantation.
  • PTLDs consist of a disease spectrum ranging from hyperplasia to aggressive lymphomas with 60-70% being Epstein-Barr virus positive.
  • The majority of cases are B-cell, although 10-15% are of T-cell origin or rarely Hodgkin lymphoma.
  • Recent SOT series suggest PTLD occurs at a median of 36-40 months after transplant.
  • Clinically, extra-nodal disease is common (up to 75-85%) including CNS involvement, which is seen in 10-15% of all cases.
  • However, recent data suggests improved survival in the modern era, especially with the integration of early rituximab-based therapy.
  • These studies utilized first line rituximab (+/- chemotherapy) together with reduced immune suppression (RI) for monomorphic and polymorphic PTLD.
  • It will be critical in future studies to determine which PTLDs are most amenable to initial therapy with RI alone, versus RI/rituximab, versus RI/rituximab/chemotherapy.
  • Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Immunosuppression / adverse effects. Lymphoproliferative Disorders / pathology. Lymphoproliferative Disorders / therapy
  • [MeSH-minor] B-Lymphocytes / immunology. B-Lymphocytes / pathology. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / therapy. Herpesvirus 4, Human. Humans. Immunotherapy, Adoptive. Morbidity. Organ Transplantation / adverse effects. Risk Factors. Rituximab. Survival Rate. T-Lymphocytes / immunology. T-Lymphocytes / pathology. Tissue Transplantation / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):313-8 [16283619.001]
  • [Cites] Am J Transplant. 2008 May;8(5):984-9 [18416737.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3622-32 [11054435.001]
  • [Cites] Blood. 1995 Jan 15;85(2):552-65 [7812011.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4002-8 [19724053.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Blood. 2009 Nov 26;114(23):4784-91 [19759356.001]
  • [Cites] Blood. 2009 Nov 26;114(23):4792-803 [19770360.001]
  • [Cites] Transplant Proc. 1969 Mar;1(1):106-12 [4944206.001]
  • [Cites] Br J Haematol. 2010 May;149(4):569-77 [20230398.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1770-9 [9884275.001]
  • [Cites] Transpl Infect Dis. 2001 Sep;3(3):177-85 [11493400.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):772-8 [11157030.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):602-12 [16889621.001]
  • [Cites] Transplantation. 1999 Mar 15;67(5):765-7 [10096538.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1076-88 [11374406.001]
  • [Cites] Haematologica. 2007 Feb;92(2):273-4 [17296588.001]
  • [Cites] Transplantation. 1995 Jan 27;59(2):240-4 [7839447.001]
  • [Cites] Am J Transplant. 2005 Dec;5(12):2894-900 [16303002.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):954-5 [15848587.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1590-7 [11238096.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4902-8 [17971586.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Am J Transplant. 2006 Mar;6(3):569-76 [16468968.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3137-47 [9787149.001]
  • [Cites] Diagn Mol Pathol. 2007 Sep;16(3):158-68 [17721324.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2960-70 [20103780.001]
  • [Cites] Transplantation. 2005 Dec 27;80(12):1692-8 [16378063.001]
  • [Cites] Transplantation. 2002 Oct 27;74(8):1095-102 [12438953.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):1038-46 [20085936.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):375-85 [10716151.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1604-12 [17122518.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2052-9 [9626203.001]
  • [Cites] Transplantation. 2005 Nov 15;80(9):1233-43 [16314791.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):70-8 [11395972.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):191-6 [15621801.001]
  • [Cites] J Clin Oncol. 2010 Nov 1;28(31):4740-6 [20837940.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1604-11 [9884246.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14 (1):15-26 [9044506.001]
  • [Cites] Transplantation. 1997 May 15;63(9):1200-5 [9158009.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1065-8 [11374404.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):104-12 [15762285.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3333-40 [7579436.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(2):193-8 [17982497.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1738-44 [18798108.001]
  • [Cites] N Engl J Med. 2000 Feb 10;342(6):440-1 [10681228.001]
  • [Cites] Br J Haematol. 2008 Jan;140(2):191-6 [18173755.001]
  • [Cites] Am J Transplant. 2007 Nov;7(11):2619-25 [17868060.001]
  • [Cites] Am J Med. 1989 Feb;86(2):241-4 [2536518.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3053-7 [16254143.001]
  • (PMID = 20963522.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


28. van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, Hählen K, Dohle GR, van den Heuvel-Eibrink MM: Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer; 2009 Jan;52(1):108-12
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of childhood cancer treatment on fertility markers in adult male long-term survivors.
  • BACKGROUND: Although it is accepted that pediatric cancer treatment harbors a risk of gonadal damage, large cohort studies using up-to-date fertility markers are lacking.
  • PROCEDURE: The aim of our study was to evaluate the gonadal toxicity of childhood cancer treatment using fertility markers.
  • Median age at diagnosis: 5 years, median age at follow-up: 24 years, median follow-up time 18 years.
  • We evaluated patient characteristics, treatment modalities, testicular size, and endocrinological parameters including Inhibin B, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone.
  • RESULTS: The median value of Inhibin B in the cancer survivor group was 126 ng/L versus 177 ng/L in the control group (P < 0.001).
  • In the survivors, 67% had Inhibin B levels below the normal reference value of 150 ng/L compared with 26% in the control group (P < 0.05).
  • Significantly decreased Inhibin B levels and increased FSH levels were found in men treated for Hodgkin and non-Hodgkin lymphoma, acute-myeloid leukemia, neuroblastoma, and sarcoma as compared to other malignancies.
  • Cumulative dosages of procarbazine and cyclophosphamide were the only independent chemotherapy-related predictors for decrease of Inhibin B levels and increase of FSH.
  • Age at time of treatment did not influence post-treatment Inhibin B or FSH levels.
  • CONCLUSIONS: Severe gonadal impairment is a risk in a considerable subgroup of childhood cancer survivors based on current fertility markers like Inhibin B.
  • Males receiving gonadotoxic treatment before puberty are not protected from post treatment gonadal dysfunction.
  • [MeSH-major] Fertility / drug effects. Infertility / diagnosis. Neoplasms / complications. Survivors
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Cyclophosphamide / adverse effects. Female. Follicle Stimulating Hormone / analysis. Follow-Up Studies. Gonads / drug effects. Gonads / physiopathology. Humans. Inhibins / analysis. Leukemia, Myeloid, Acute / complications. Lymphoma / complications. Male. Neuroblastoma / complications. Procarbazine / adverse effects. Sarcoma / complications

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Infertility.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819129.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / inhibin B; 35S93Y190K / Procarbazine; 57285-09-3 / Inhibins; 8N3DW7272P / Cyclophosphamide; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


29. Maisey NR, Hill ME, Webb A, Cunningham D, Flux GD, Padhani A, Ott RJ, Norman A, Bishop L: Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer; 2000 Jan;36(2):200-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
  • Treatment of both Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) frequently results in a residual mass visible radiologically.
  • Such patients may receive radiotherapy unnecessarily because the residual mass may represent benign fibrotic tissue rather than residual active lymphoma.
  • A number of clinical investigations have been evaluated to more accurately determine the nature of such lesions, including erythrocyte sedimentation rate (ESR), magnetic resonance imaging (MRI) and high-dose gallium-67 scanning (HDGS) but none has proven utility.
  • 18[F]-fluorodeoxyglucose positron emission tomography (FDG-PET) is an imaging technique that has been shown to be useful in distinguishing fibrosis from residual active disease in solid tumours.
  • The aim of this study was to compare FDG PET and MRI in the assessment of residual masses following treatment for lymphoma.
  • Patients with NHL/HD who had a residual mass following chemotherapy were eligible for this study.
  • All scans were completed within 5 months of the end of treatment.
  • There was a trend for improved relapse-free survival (RFS) with a negative result of both MRI and PET, but this was not statistically significant.
  • The predictive value for both tests failed to reach statistical significance.
  • There is no convincing evidence that either MRI or PET or the combination can reliably predict relapse within residual masses after treatment for lymphoma.
  • A negative PET scan however appears to be more informative than a positive result and may well aid clinical decision making.
  • There are a number of factors that may produce false-positive results, including post-treatment inflammatory changes, the sensitivity of the test in the setting of minimal residual disease and the heterogeneity of the histological subtypes studied.
  • A negative PET (or MRI) result in lymphoma residual masses following therapy may negate the necessity for further therapy such as chemotherapy or radiotherapy and their concomitant toxicities.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm, Residual. Recurrence. Tomography, Emission-Computed / methods

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741278.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


30. Gupta S, Kumar L, Raju GM, Kochupillai V, Shukla DK: Autologous bone marrow/stem cell transplantation: initial experience at a north Indian referral centre. Natl Med J India; 2000 Mar-Apr;13(2):61-6
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous bone marrow/stem cell transplantation: initial experience at a north Indian referral centre.
  • BACKGROUND: High-dose chemotherapy and/or radiation therapy rescued by autologous bone marrow or peripheral blood stem cells is being increasingly used for the treatment of haematological and solid malignancies.
  • While few centres in India use this modality of therapy, the worldwide experience is encouraging.
  • We, therefore, analysed the results of our initial experience with this therapeutic modality.
  • METHODS: Forty-two patients [multiple myeloma (17), Hodgkin's disease (4), non-Hodgkin's lymphoma (3), chronic myeloid leukaemia (2), acute myeloid leukaemia (2), acute lymphoblastic leukaemia (2), epithelial ovarian cancer (6), breast cancer (4), primitive neuroectodermal tumour and testicular germ cell tumour (1 each)] underwent high-dose chemotherapy followed by either autologous bone marrow transplant (n = 9), peripheral blood stem cell transplant (n = 30) or both (n = 3).
  • The indications for transplant included either advanced stage at diagnosis, other adverse prognostic indicators during the course of their disease, or relapse.
  • Eight patients (19%) died in the early post-transplant period (day 5 to day 52 post-transplant).
  • Of the 34 surviving patients, 20 were alive at the time of analysis and 14 had died.
  • An analysis of factors affecting survival revealed that patients with chemosensitive disease had a longer overall survival (20.9 v. 6.1 months, p = 0.04) compared to those with chemoresistant disease.
  • CONCLUSION: Autologous bone marrow or peripheral stem cell transplantation is a feasible procedure in India with an acceptable morbidity and mortality.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. India / epidemiology. Leukemia / mortality. Leukemia / therapy. Lymphoma / mortality. Lymphoma / therapy. Male. Middle Aged. Neoplasms / mortality. Neoplasms / therapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10835851.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


31. Ståhl O, Eberhard J, Cavallin-Ståhl E, Jepson K, Friberg B, Tingsmark C, Spanò M, Giwercman A: Sperm DNA integrity in cancer patients: the effect of disease and treatment. Int J Androl; 2009 Dec;32(6):695-703

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm DNA integrity in cancer patients: the effect of disease and treatment.
  • As oncological treatment might impair the patients' fertility, male cancer patients are offered to cryopreserve semen prior to treatment.
  • Therefore, we have assessed sperm DNA integrity in cancer patients, comparing pre- and post-treatment quality.
  • Sperm DNA integrity was investigated in cryopreserved semen from 121 cancer patients, the predominating diagnoses were germ cell cancer (GCC) and Hodgkin's lymphoma (HL).
  • Post-treatment samples, with a median follow-up of 3 years, were analysed for 58 of the men, allowing a pre- and post-treatment analysis on an individual basis.
  • Sperm DNA integrity was assessed using the Sperm Chromatin Structure Assay and expressed here as the DNA Fragmentation Index (DFI%).
  • Before treatment, GCC (n = 84) and HL (n = 18) patients had higher DFI% than controls (n = 143) with a mean difference of 7.7 (95% CI 3.2-8.8) and 7.0 (95% CI 2-12), respectively.
  • The same trend was observed for other cancer diagnoses, but without reaching statistical significance (mean difference 3.6, 95% CI -1.2 to 8.4).
  • No increase was seen in DFI% comparing pre- and post-treatment semen, regardless of treatment modality.
  • Oncological treatment, generally, did not induce any increase in DFI.
  • These findings should be considered when discussing the utilization of pre-treatment cryopreserved semen vs. post-treatment fresh sperm in cancer patients undergoing assisted reproduction.
  • [MeSH-major] DNA / genetics. Neoplasms / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Neoplasms, Germ Cell and Embryonal / therapy. Spermatozoa / drug effects
  • [MeSH-minor] Adult. Cryopreservation. DNA Fragmentation / drug effects. Fertility / genetics. Humans. Male. Semen / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178596.001).
  • [ISSN] 1365-2605
  • [Journal-full-title] International journal of andrology
  • [ISO-abbreviation] Int. J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


32. Ozdemir F, Aydin F, Yilmaz M, Kavgaci H, Bektas O, Yavuz MN, Yavuz AA: The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL). J Exp Clin Cancer Res; 2004 Sep;23(3):485-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
  • The aim of this study was to investigate serum levels of IL-2, IL-6 and IL-10 in the pretreatment period and to determine if high IL-2, IL-6, IL-10 levels correlate with the outcome in patients with Non-Hodgkin's Lymphoma (NHL) in the post treatment period.
  • Forty-three patients with the diagnosis of aggressive NHL were included in our study.
  • In all cases initial treatment consisted of CHOP.
  • Patients who failed initial therapy and relapsed from CR were treated with the ESHAP regimen or autologous bone marrow transplantation.
  • IL-6 and IL-10 levels did not affect overall survival.
  • In conclusion, in patients with lymphoma, the immune system tries to control the progression of tumor thus leading to high IL-2 levels.
  • [MeSH-major] Interleukin-10 / blood. Interleukin-2 / blood. Interleukin-6 / blood. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Enzyme-Linked Immunosorbent Assay. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma / drug therapy. Male. Methylprednisolone / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Regression Analysis. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15595640.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Interleukin-6; 04079A1RDZ / Cytarabine; 130068-27-8 / Interleukin-10; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; CHOP protocol; ESAP protocol
  •  go-up   go-down


33. Korab Chrzanowska E, Bartoszewska J: [Radiotherapy as a one of the three standard methods of oncological treatment in children. Assesment based on 6 years activity of the first department of paediatric radiotherapy in Poland, localized in the paediatric hospital]. Przegl Lek; 2007;64(12):1010-3
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy as a one of the three standard methods of oncological treatment in children. Assesment based on 6 years activity of the first department of paediatric radiotherapy in Poland, localized in the paediatric hospital].
  • OBJECTIVE: The purpose of this paper was to evaluate activity of the Radiotherapy Department by measuring quality of delivered therapy.
  • MATERIAL AND METHODS: Between November 1999 and November 2005, 305 patients, including 172 boys and 133 girls from 2 to 18-years-old, underwent irradiation in the Radiotherapy Department, University Children's Hospital of Cracow.162 patients were treated because of proliferative diseases of the hematopoietic system--96 children were diagnosed with leukemia and non-Hodgkin lymphoma, 66 children suffered from Hodgkin's disease.
  • 67 children had CNS tumors, 35 had soft tissue or bone sarcomas, 20--neuroblastoma, 12--Wilm's tumor, and 9 were diagnosed with other malignancies.
  • RESULTS: 293 children (96%) received radical treatment, and 12 paediatric patients (4%) underwent palliative irradiation.
  • During these 6 years, a systematic increase in the share of conformal techniques in all therapeutic methods used in the Radiotherapy Department was observed.
  • Currently, the conformal techniques are used for every patient treated radically.
  • Severe post-radiation reaction (G3, G4) was observed in 3 children, who were receiving chemotherapy with radio-sensitizers at the same time.
  • CONCLUSIONS: Oncological treatment for children provided in the one centre is a good option for paediatric patients.
  • [MeSH-major] Delivery of Health Care. Neoplasms / classification. Neoplasms / radiotherapy. Radiation Injuries. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Poland. Quality of Health Care. Treatment Outcome


34. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN: 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma; 2000 Nov;39(5-6):543-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
  • Less than 50% of newly diagnosed patients with aggressive histology Non-Hodgkin's Lymphoma (NHL) are cured with standard treatment.
  • The ability to accurately monitor response to treatment is crucial in order to select out patients who need more intensive or salvage treatment.
  • This study assesses the accuracy of FDG-PET as compared to CT in remission assessment following treatment of aggressive NHL, and its value in estimating relapse-free survival.
  • It also evaluates the prognostic value of early interim PET scan in prediction of treatment outcome.
  • All patients had pre-treatment FDG-PET demonstrating increased uptake in sites of disease.
  • Forty-five patients had a post-treatment PET to assess remission status and 4 had an interim but not a post-treatment PET.
  • Thirty-three of these patients also had a pre- and a post-treatment CT scan.
  • Twenty-three of the 49 patients had an interim PET during chemotherapy to assess early response.
  • Overall the result of post-treatment PET scan appears to predict disease outcome, with relapse rates of 100% (9/9) and 17% (6/36) for positive and negative PET respectively [p<0.001].
  • In a subgroup of 33 patients, direct comparison of post-treatment PET and CT shows that PET was more accurate than CT in assessing remission status following treatment.
  • FDG-PET is an accurate method of assessing remission and estimating prognosis following treatment of aggressive NHL, with positive and negative predictive accuracies of 100% and 82% respectively.
  • An interim PET scan after 2-3 cycles of chemotherapy predicts the long-term outcome early-on and has a high negative predictive value (100%).
  • This may assist to separate at an early stage good-prognosis patients who are likely to be cured with standard chemotherapy from those patients with poorer prognosis who require alternative treatment.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / diagnosis. Tomography, Emission-Computed / methods
  • [MeSH-minor] Adult. Age Factors. Aged. Cohort Studies. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Male. Middle Aged. Predictive Value of Tests. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Spleen / pathology. Spleen / radionuclide imaging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342337.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Agarwal A: Semen banking in patients with cancer: 20-year experience. Int J Androl; 2000;23 Suppl 2:16-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modern techniques of banking sperm provide an effective way to preserve the option of future fertility for most teenagers and young men diagnosed with a variety of malignancies that will necessitate treatment with chemotherapy, pelvic surgery, or significant radiation doses to the testes.
  • Results of cumulative data collected at the Cleveland Clinic Foundation from patients with testicular cancer, lymphoma, leukemia, sarcoma, carcinoma and other kinds of malignancy have revealed that:.
  • (1) pretreatment semen quality (pre-freeze and post-thaw) in patients with cancer is poorer compared with healthy donors;.
  • (2) the percentage decline in semen quality (from pre-freeze to post-thaw) in patients with cancer is similar to that of normal donors.
  • This suggested that the effect of cryodamage on spermatozoa from patients with cancer is similar to that of normal donors. (3) The stage of cancer in patients with testicular cancer and Hodgkin's disease shows no relationship to their semen quality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10849486.001).
  • [ISSN] 0105-6263
  • [Journal-full-title] International journal of andrology
  • [ISO-abbreviation] Int. J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


36. Punwani S, Prakash V, Bainbridge A, Taylor SA, Bandula S, Olsen OE, Hain SF, Shankar A, Daw S, Humphries P: Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma? Cancer Biomark; 2010;7(4):249-59
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma?
  • PURPOSE: This study explores the relationship between MRI Apparent Diffusion Coefficient (ADC) and PET Standardized Uptake Value (SUV) measurements in pediatric Hodgkin lymphoma.
  • METHODS: Sixteen patients (mean age 15.4 yrs, 8 male) with proven Hodgkin lymphoma were recruited and staged using PET-CT, anatomical MRI and additional 1.5T diffusion weighted imaging (DWI) prior to and following chemotherapy.
  • Pre-treatment lymph nodes and anatomically paired post-treatment residual tissue located on MRI were matched to the corresponding PET-CT.
  • Pre- and post-treatment ADC(mean) ranged from 0.77 × 10(−3) to 1.79 × 10(−3) (median 1.15 × 10(−3) mm(2)s(−1)) and 1.08 × 10(−3) to 3.18 ×10(−3) (median 1.88 × 10(−3) mm(2)s(−1)), and SUV(max) from 2.60 to 25.4 (median 8.85 mg/ml) and 1.00 to 3.50 mg/ml (median 1.90 mg/ml).
  • Median post-treatment ADC(mean) was higher, and median SUV(max) lower than pretreatment values (p < 0.0001).
  • There was an inverse correlation between pre-treatment ADC(mean) and SUV(max) (p = 0.005) and between fractional change ([post-treatment – pre-treatment]/pre-treatment)in ADC(mean) and SUV(max) (p =0.002).
  • CONCLUSION: Our results confirm a strong reciprocal relationship between nodal ADC(mean) and SUV(max) in Hodgkin lymphoma;supporting the potential application of quantitative DWI as a functional biomarker of disease.
  • [MeSH-major] Biomarkers, Tumor. Diffusion Magnetic Resonance Imaging. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adolescent. Child. Female. Humans. Male. Neoplasm Staging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21576817.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Göksan B, Karaali-Savrun F, Ertan S, Savrun M: Haemodialysis-related headache. Cephalalgia; 2004 Apr;24(4):284-7
Hazardous Substances Data Bank. UREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dialysis may induce severe headache as a result of a large amount of water and electrolyte shifts.
  • It is important to recognize it because it can be a great problem to the patient and changing dialysis parameters or methods can prevent it.
  • In this study we investigated the frequency and clinical characteristics of headaches occurring during haemodialysis (HD).
  • Thirty female and 33 male patients with chronic renal failure on regular dialysis for at least 6 months in the HD unit of the Internal Medicine Department from 1996 to 2000 participated in the study.
  • The dialysis solution contained acetate in 35 patients and bicarbonate in 28 patients.
  • In all patients capillary dialysers and Cuprophan membranes were used and every session of dialysis lasted 4 h.
  • Dialysis headache (DH) diagnosis was made according to the criteria of the International Headache Society.
  • Patients with primary headache and under drug treatment during HD, which can cause headache, were excluded from the study.
  • The frequency of DH, its relation to gender, age, dialysis technique and parameters and its features were investigated.
  • DH was detected in 48% (n = 30) of the study group.
  • Compared with dialysis solutions, no difference was found between patients with and without DH.
  • The difference in the pre- and post-dialysis value of urea in patients with DH was statistically significant (P < 0.05).
  • Patients with DH showed significantly higher mean systolic and diastolic blood pressure predialysis values in comparison with patients without DH (systolic, P < 0.001; diastolic, P < 0.01), whereas post-treatment values did not differ between the two groups.
  • Fronto-temporal location, moderate severity, throbbing quality and short duration (<4 h) were the most prevalent features of DH in patients.
  • [MeSH-major] Headache / etiology. Renal Dialysis / adverse effects
  • [MeSH-minor] Adult. Blood Pressure. Female. Hemodialysis Solutions. Humans. Kidney Failure, Chronic / therapy. Male. Middle Aged. Sex Factors. Urea / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15030537.001).
  • [ISSN] 0333-1024
  • [Journal-full-title] Cephalalgia : an international journal of headache
  • [ISO-abbreviation] Cephalalgia
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemodialysis Solutions; 8W8T17847W / Urea
  •  go-up   go-down


38. Tuli MM, Al-Shemmari SH, Ameen RM, Al-Muhanadi S, Al-Huda FA, Ballani N, Khoshi M, Al-Enezi F, Bajciova V, Mottl H: The use of gallium-67 scintigraphy to monitor tumor response rates and predict long-term clinical outcome in patients with lymphoma. Clin Lymphoma; 2004 Jun;5(1):56-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of gallium-67 scintigraphy to monitor tumor response rates and predict long-term clinical outcome in patients with lymphoma.
  • The aim of this study was to determine whether gallium (Ga)-67 scintigraphy can monitor the treatment response rates and predict the long-term clinical outcome in patients with lymphoma.
  • Gallium-67 scintigraphy was performed upon admission (baseline Ga) in 33 consecutive, newly diagnosed patients.
  • Twenty-eight patients (Hodgkin's disease, n = 18; non-Hodgkin's lymphoma, n = 13) with Ga avid tumors were included in the study.
  • All the patients were treated with induction chemotherapy.
  • Gallium-67 scintigraphy was performed in all patients after the first cycle of chemotherapy (post-cycle 1 Ga) and repeated after the fourth cycle (post-cycle 4 Ga) or after completion of treatment (end-of-chemotherapy Ga).
  • Nineteen patients had a fast response (68%, negative in post-cycle 1 and end-of-chemotherapy Ga), 4 intermediate response (14%, partial positive post-cycle 1 Ga that progressed to negative post-cycle 4 Ga), 3 slow response (11%, partial positive in both post-cycle 1 and post-cycle 4 Ga) and 2 no response (7%, positive in both post-cycle 1 and end-of-chemotherapy Ga).
  • In patients who had either fast or intermediate response, 22 (96%) were free of disease at a median follow-up period of 30 months (range, 11-45 months).
  • All 5 patients (100%) who had slow or no response had progressive disease or residual disease.
  • In conclusion, the findings indicate that Ga could effectively be used to monitor the treatment response rates and predict the long-term clinical outcome in patients with lymphoma and should be used in treatment modifications aimed at reducing toxicity of effective therapy in patients with fast response and replacing treatments early in patients with slow or no response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallium Radioisotopes. Lymphoma / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Female. Follow-Up Studies. Hodgkin Disease / drug therapy. Hodgkin Disease / radionuclide imaging. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Middle Aged. Survival Analysis. Time Factors. Tissue Distribution. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15245609.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes
  •  go-up   go-down


39. Zinzani PL, Tani M, Alinari L, Molinari AL, Stefoni V, Visani G, Gentilini P, Guardigni L, Fina M, Baccarani M: Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. Leuk Lymphoma; 2005 Oct;46(10):1449-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy.
  • Baseline anemia is a relevant prognostic factor in the overall population of non-Hodgkin's lymphoma (NHL) patients, and studies focusing on elderly NHL are awaited.
  • We conducted a pooled analysis of a cohort of comparable patients enrolled (1993 - 2001) in three multicenter clinical trials on use of a MACOP-B-like regimen (VNCOP-B) for front-line treatment of elderly aggressive NHL.
  • Models of Cox's proportional hazards regression analysis of prognostic value of pre-/post-treatment hemoglobin values in terms of 5-year overall survival included age, sex, initial tumor staging and response to treatment.
  • In addition to achievement of complete/partial remission (adjusted relative risk [RR], 0.215; p = 0.0001) and advanced stage (II-IV vs. I - II; adjusted RR, 1.55; p = 0.0023), post-treatment hemoglobin values were an independent predictor of survival (adjusted RR per 1-g/dL increment, 0.76; p = 0.0041).
  • Post-treatment hemoglobin values appear to provide a strong independent predictor of 5-year survival in elderly aggressive NHL, supporting the potential role of anemia correction in this group of patients.
  • [MeSH-major] Anemia / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194890.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Sinitsyn Y, Malone A, Mandeli J, Grosskreutz C, Osman K, Scigliano E, Shi P, Isola L: Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization. Cytotherapy; 2009;11(4):457-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mobilization was with filgrastim (10 microg/kg/day) alone for 5 days or after chemotherapy.
  • The diagnoses were multiple myeloma (7), non-Hodgkin's lymphoma (7), Hodgkin's disease (4) and acute myeloid leukemia (1).
  • Six patients died of progressive disease (58-293 days post-ASCT), one of infection on day 141 and one of AML on day 11.
  • One patient had cholecystitis and delayed graft failure on day 90.
  • PBPC CD34+ content did not predict CD34+ BM content but correlated with ANC > 500 (r= - 0.64, P=0.003).
  • BM and combined CD34+ and BM TNC/kg did not correlate with engraftment or outcomes.
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Blood Platelets / cytology. Female. Humans. Male. Middle Aged. Neutrophils / cytology. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499401.001).
  • [ISSN] 1477-2566
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


41. Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ: ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer; 2010 May-Jun;34(3):211-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma.
  • In the follow-up of Hodgkin's lymphoma patients, the focus in the first 5 years is to detect recurrence, while after 5 years, the focus is on limiting and detecting late effects of treatment.
  • In the first 5 years post-treatment, routine history and physical and computed tomography (CT) imaging (more frequent in the first 2 years) are generally appropriate.
  • However, there are limited data to support the role of positron emission tomography scanning as routine follow-up.
  • Beyond 5 years post-treatment, annual history and physical is appropriate, although there is no longer a role for routine imaging for recurrences.
  • Women irradiated to the chest area at a young age (<35) would benefit from annual mammogram screening given the increased breast cancer risk.
  • Low-dose chest CT for lung cancer screening in patients with history of mediastinal irradiation and/or alkylating chemotherapy exposures and a smoking history can be considered, although data on its utility is lacking.
  • Cardiac screening with echocardiogram and exercise tolerance tests in patients with history of mediastinal irradiation and/or adriamycin exposure may be appropriate, although the optimal screening interval would depend on mediastinal dose, adriamycin dose, presence of other cardiac risk factors and findings at the baseline screening.
  • Patients at risk for cardiac disease due to treatment exposure would also benefit from lipid screening every 1-3 years.
  • [MeSH-major] Guideline Adherence. Hodgkin Disease / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis. Practice Guidelines as Topic
  • [MeSH-minor] Combined Modality Therapy. Diagnostic Imaging. Female. Follow-Up Studies. Humans. Male. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American College of Radiology. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20541059.001).
  • [ISSN] 1535-6345
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


42. Moralidis E, Mandala E, Venizelos I, Arsos G, Zafiriadu E, Goutzioulis M, Karakatsanis C: A breast fibroadenoma mimicking an extranodal deposit of Hodgkin's lymphoma in 67Ga imaging. Br J Radiol; 2009 Mar;82(975):e58-62
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A breast fibroadenoma mimicking an extranodal deposit of Hodgkin's lymphoma in 67Ga imaging.
  • We present the case of a young woman with classical nodular sclerosing Hodgkin's lymphoma (clinical stage IIB).
  • During staging work-up, intense gallium-67 ((67)Ga) accumulation in a left breast lump raised the suspicion of an extranodal deposit, but biopsy favoured a benign histology.
  • A post-treatment (67)Ga scan showed complete remission of the disease with normal tracer uptake in the left breast.
  • However, a few months after treatment, a faint left mammary concentration of (67)Ga was observed.
  • This unusual presentation is a new addition to the literature on false-positive (67)Ga findings and chemotherapy-associated tracer changes.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Contrast Media. Fibroadenoma / radionuclide imaging. Gallium Radioisotopes. Hodgkin Disease / radionuclide imaging
  • [MeSH-minor] Diagnosis, Differential. False Positive Reactions. Female. Humans. Lymphatic Metastasis. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211906.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Gallium Radioisotopes
  •  go-up   go-down


43. Jenkins D, DiFrancesco L, Chaudhry A, Morris D, Glück S, Jones A, Woodman R, Brown CB, Russell J, Stewart DA: Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplant; 2002 Sep;30(5):321-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients.
  • We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma.
  • The first two cases received ASCT for MM, one with a CD34-selected autograft and the other with an unmanipulated autograft.
  • Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN).
  • The third case received ASCT with an unmanipulated autograft for relapsed angioimmunoblastic lymphoma.
  • These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.
  • They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.
  • [MeSH-major] Lymphoproliferative Disorders / drug therapy. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antiviral Agents / administration & dosage. Diagnosis, Differential. Humans. Immunoblastic Lymphadenopathy / complications. Immunoblastic Lymphadenopathy / therapy. Immunotherapy. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / complications. Multiple Myeloma / therapy. Remission Induction / methods. Transplantation, Autologous / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12209355.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents
  •  go-up   go-down


44. Bokemeyer C, Oechsle K, Hartmann JT, Schöffski P, Schleucher N, Metzner B, Schleicher J, Kanz L: Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer; 2002 Nov 4;87(10):1066-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer.
  • First-line sequential high dose chemotherapy is under investigation in patients with "poor prognosis" metastatic germ cell tumours in order to improve survival.
  • Despite the use of autologous peripheral blood stem cell transplantation and granulocyte colony stimulating factor chemotherapy dose intensification is associated with severe haematotoxicity including anaemia, which may significantly affect quality of life and tolerability of chemotherapy.
  • This study investigates the frequency and degree of anaemia in patients receiving first-line sequential high dose chemotherapy for metastatic testicular cancer and the impact of anaemia on treatment outcome.
  • A total of 101 newly diagnosed patients with "poor prognosis" metastatic nonseminomatous germ cell tumours were treated with one cycle of standard VIP followed by three cycles of HD-VIP-chemotherapy (etoposide, ifosfamide, cisplatin) within a large phase I/II study.
  • Differential blood cell counts were taken prior, during and after every cycle of chemotherapy.
  • Kaplan-Meier analyses were performed to correlate pre-treatment and post-treatment haemoglobin values to response and overall survival.
  • Forty-eight per cent of the patients were classified anaemic (haemoglobin <12 g dl(-1)) prior to the start of chemotherapy.
  • The application of sequential HD-VIP resulted in median haemoglobin nadirs between 7.8 g dl(-1) (range 5.5-11.1 g dl(-1)) in the first cycle and 7.6 g dl(-1) (range 6.0-11.4 g dl(-1)) in the third cycle despite the frequent use of red blood cell transfusions.
  • Almost all patients (99%) had haemoglobin levels <10 g dl(-1) at some timepoint during first-line sequential high dose chemotherapy.
  • Overall, 97 patients received red blood cell transfusions with a median of 10 units (range 2-25) per patient during the four consecutive cycles of therapy.
  • The time to first transfusion was shortest in patients with the lowest initial haemoglobin values.
  • While there was no prediction of response or outcome by baseline haemoglobin-levels, a significant survival difference in favour of patients with a haemoglobin value >10.5 g dl(-1) after completion of four cycles of therapy (at leukocyte recovery after the last cycle) compared to those with haemoglobin values <10.5 g dl(-1) was found with 3-year overall survival rates of 87% vs 68%, respectively (P<0.05).
  • Severe anaemia is a very frequent side effect of sequential dose intensive therapy in patients with germ cell cancer, with almost all patients becoming transfusion dependent.
  • Despite the frequent use of red blood cell transfusions, median haemoglobin nadirs remained about 7.5-8 g dl(-1) during therapy.
  • A correlation of haemoglobin-values after completion of therapy to overall treatment outcome was found.
  • [MeSH-major] Anemia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Germinoma / drug therapy. Testicular Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Testicular cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Cancer Research UK
  • [Cites] Haematologica. 2000 Feb;85(2):219-20 [10681739.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):93-7 [10638973.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:250-67 [10800487.001]
  • [Cites] Cancer Treat Rev. 2000 Aug;26(4):303-11 [10913385.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1304-15 [11283931.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2865-74 [11387359.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2875-82 [11387360.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):865-72 [11429213.001]
  • [Cites] Curr Opin Oncol. 1995 Jul;7(4):316-9 [7578378.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):24-32; discussion 45-8 [9578059.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):23-6 [9671326.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):35-8 [9671328.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):54-7 [9671332.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):726-31 [9708937.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:17-9 [9879342.001]
  • [Cites] Oncology. 1999;56(1):46-53 [9885377.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):396-402 [10408844.001]
  • [Cites] Drugs. 1999 Aug;58(2):257-81 [10473019.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3450-6 [10550141.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2840-6 [10561360.001]
  • [Cites] Eur J Cancer. 2000 May;36(7):852-7 [10785589.001]
  • (PMID = 12402143.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Other-IDs] NLM/ PMC2376199
  •  go-up   go-down


45. Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS: [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma; 2009 Jun;50(6):904-11
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
  • Rituximab is a chimeric anti-CD20 monoclonal antibody widely used in the treatment of B-cell non-Hodgkin lymphomas (NHL).
  • We retrospectively reviewed clinical data and serial imaging studies of five patients with NHL treated with rituximab-containing chemotherapy who developed new pulmonary abnormalities on routine follow-up FDG-PET/CT imaging.
  • None of the patients had pulmonary lymphoma or other pulmonary disease before therapy and all remained asymptomatic during follow-up.
  • New pulmonary interstitial FDG-uptake was detected on follow-up FDG-PET/CT between 1 and 3 months post-treatment, preceded computed tomography abnormalities in one case, and persisted for several months.
  • FDG uptake was linear, subpleural with maximum Standardized uptake value (SUV) from 2.0 to 5.84.
  • Rituximab-containing chemotherapy for NHL may be associated with asymptomatic late pulmonary toxicity characterised by a distinct FDG uptake pattern.
  • Awareness of this finding is important and should not be confused with lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Lung / drug effects. Lung / metabolism. Lung / pathology. Lung Diseases / chemically induced. Lung Diseases / diagnosis. Male. Retrospective Studies. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Jun;50(6):865-7 [19504393.001]
  • (PMID = 19455459.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


46. Brydøy M, Fosså SD, Dahl O, Bjøro T: Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol; 2007;46(4):480-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadal dysfunction and fertility problems in cancer survivors.
  • Gonadal dysfunction and fertility problems are adverse effects of cancer treatment or may be associated with specific malignancies.
  • In females, treatment adverse effects can result in infertility, but premature ovarian failure (POF) is probably relevant for more female cancer survivors, affecting also those who do not wish post-treatment parenthood.
  • However, a recent long-term follow-up study reported a prevalence of POF in young females with Hodgkin's lymphoma of 37% showing that young age at time of treatment only delays the development of POF.
  • In male gonads, germ cells are much more sensitive to irradiation and chemotherapy than Leydig cells.
  • Persistent azoospermia was formerly common after treatment for Hodgkin's lymphoma, but currently, most patients recover spermatogenesis.
  • Modern treatment of childhood acute lymphoblastic leukemia is also unlikely to cause infertility.
  • Norwegian testicular cancer survivors diagnosed in 1980-1994 who attempted conception had an overall 15-year actuarial post-treatment paternity rate of 71% (range 48-92% depending on the treatment).
  • However, the rate was significantly higher among men diagnosed in1989-1994 (over 80%) than in 1980-1988 (about 63%).
  • Patients at risk for hypogonadism and infertility should be defined prior to treatment, and available methods for gonadal preservation should maximally be utilised.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Gonadal Disorders / etiology. Infertility / etiology. Neoplasms. Radiotherapy / adverse effects. Survivors


47. Goldblum D, Ghadjar P, Curschmann J, Greiner R, Aebersold D: Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Radiat Oncol; 2008;3:22
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.
  • METHODS: Five patients (2 males, 3 females) with diagnosed malignancies (Non-Hodgkin B-cell Lymphoma, neuroendocrine carcinoma) involving the lacrimal gland, in which either combined CT-RT or local RT were indicated, were prophylactically treated with amifostine (500 mg sc).
  • Single RT fraction dose, total dose and treatment duration were individually adjusted to the patient's need.
  • Subjective and objective dry eye assessment was performed for the post-treatment control of lacrimal gland function.
  • The median total duration of RT was 29 days (range, 23 - 39 days) and the median total RT dose was 40 Gy (range, 36 - 60 Gy).
  • Median lacrimal gland exposure was 35.9 Gy (range, 16.8 - 42.6 Gy).
  • Very good partial or complete tumor remission was achieved in all patients.
  • The treatment was well tolerated without major toxic reactions.
  • Post-treatment control did not reveal in any patient either subjective or objective signs of a dry eye syndrome.
  • [MeSH-major] Amifostine / therapeutic use. Dry Eye Syndromes / prevention & control. Lacrimal Apparatus / pathology. Orbital Neoplasms / drug therapy. Orbital Neoplasms / radiotherapy. Radiation-Protective Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / radiotherapy. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Male. Middle Aged. Pilot Projects

  • Bern Open Repository and Information System. Free Full text from BORIS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8):1155-62; discussion 1162-9 [11236308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):739-47 [11849797.001]
  • [Cites] Anticancer Drugs. 2002 Mar;13(3):181-209 [11984063.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):818-23 [12377334.001]
  • [Cites] Arch Ophthalmol. 1969 Jul;82(1):10-4 [4183019.001]
  • [Cites] Am J Ophthalmol. 1991 Jan 15;111(1):106-8 [1985472.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1035-9 [11072160.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] CLAO J. 1995 Oct;21(4):221-32 [8565190.001]
  • [Cites] Ann Oncol. 1998 May;9(5):505-9 [9653491.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1347-55 [17318564.001]
  • [Cites] Strahlenther Onkol. 1999 Nov;175 Suppl 4:30-3 [10584138.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] J Am Dent Assoc. 1991 Mar;122(3):63-9 [2019691.001]
  • (PMID = 18761746.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  • [Other-IDs] NLM/ PMC2542992
  •  go-up   go-down


48. Choi JH, Park BB, Suh C, Won JH, Lee WS, Shin HJ: Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders. J Korean Med Sci; 2010 Apr;25(4):523-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
  • Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative disorders associated with immunosuppression and Epstein-Barr virus infection.
  • The majority of monomorphic PTLD cases are non-Hodgkin's lymphoma of B-cell origin.
  • This retrospective study was conducted to investigate the incidence, clinical manifestation, treatment, and outcomes of monomorphic PTLD among 5,817 recipients of solid organ or allogeneic hematopoietic stem cell transplantation from five institutions.
  • The most common disease type was diffuse large B cell lymphoma (n=7).
  • The median time between the transplant and diagnosis of PTLD was 85.8 months.
  • Ten of the 14 patients had EBV-positive tumor.
  • Fourteen patients received combination systemic chemotherapy and four patients were treated with radiation therapy.
  • Ten patients achieved a complete response (CR) and two patients a partial response (PR).
  • Nine patients remain alive (eight CR, one PR).
  • The present study indicates a lower incidence rate and a longer median time before the development of PTLD than those of previous reports.
  • [MeSH-minor] Adult. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Female. Herpesvirus 4, Human. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):375-85 [10716151.001]
  • [Cites] Blood. 1994 May 1;83(9):2715-22 [8167350.001]
  • [Cites] Bone Marrow Transplant. 2009 Feb;43(4):315-21 [18836488.001]
  • [Cites] Transplantation. 2005 Jan 27;79(2):244-7 [15665775.001]
  • [Cites] Oncologist. 2006 Jun;11(6):674-80 [16794246.001]
  • [Cites] Am J Hematol. 2007 Mar;82(3):208-14 [17022049.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2052-9 [9626203.001]
  • (PMID = 20357991.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2844611
  • [Keywords] NOTNLM ; Monomorphic Post-transplant Lymphoproliferative Disorders
  •  go-up   go-down


49. Bitzan M, Ouahed JD, Carpineta L, Bernard C, Bell LE: Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol; 2010 Jun;25(6):1163-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.
  • We describe an 11-year-old girl with Epstein-Barr virus (EBV) reactivation/presumed post-transplant lymphoproliferative disease (PTLD) 15 months after undergoing a deceased donor kidney transplantation.
  • Treatment with reduced immunosuppression, ganciclovir, and cytomegalovirus immunoglobulin was complicated by severe graft rejection, prompting therapy with methylprednisolone, anti-thymocyte globulin and four weekly doses of rituximab (total 1500 mg/m(2)).
  • Tacrolimus- and prednisone-based anti-rejection prophylaxis was complemented with low-dose sirolimus.
  • When the lactate dehydrogenase and uric acid levels rose 10 weeks after the first rituximab infusion and bilateral pulmonary nodules were detected by computerized tomography, recurrence of PTLD was suspected.
  • Open lung biopsy of the clinically asymptomatic patient identified the nodules as COP, characterized by abundant CD3(+) T-cells, few B-cells, and the absence of EBV, cytomegalovirus, or adenovirus antigens.
  • Four years later, the patient was diagnosed with classical Hodgkin lymphoma-type PTLD with multiple pulmonary and abdominal nodes.
  • This first report of rituximab-associated, pediatric COP highlights the risk of pulmonary complications after treatment with B-cell depleting agents in solid organ transplant recipients, and the importance of a histopathologic diagnosis and vigilant follow-up of such lesions.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Bronchiolitis Obliterans / chemically induced. Immunologic Factors / adverse effects. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Child. Epstein-Barr Virus Infections / complications. Female. Graft Rejection / pathology. Graft Rejection / therapy. Humans. Rituximab

  • Genetic Alliance. consumer health - Cryptogenic Organizing Pneumonia.
  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 2010 Mar;35(3):681-7 [19608586.001]
  • [Cites] Br J Haematol. 2008 Feb;140(4):429-32 [18162118.001]
  • [Cites] Pediatr Pulmonol. 2009 Sep;44(9):922-34 [19681063.001]
  • [Cites] Joint Bone Spine. 2008 May;75(3):362-5 [18424211.001]
  • [Cites] Ther Adv Respir Dis. 2008 Oct;2(5):319-38 [19124380.001]
  • [Cites] Arch Intern Med. 2001 Jan 22;161(2):158-64 [11176728.001]
  • [Cites] Respiration. 2008;76(4):449-53 [17596682.001]
  • [Cites] Pediatr Pulmonol. 1996 Jul;22(1):67-72 [8856805.001]
  • [Cites] Pediatr Nephrol. 2009 Apr;24(4):731-6 [17891420.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):916-9 [17597477.001]
  • [Cites] Pediatr Pulmonol. 2004 Nov;38(5):369-78 [15376335.001]
  • [Cites] Transplantation. 2001 Sep 15;72(5):787-90 [11571438.001]
  • [Cites] Curr Opin Pulm Med. 2005 Sep;11(5):422-30 [16093817.001]
  • [Cites] Am J Transplant. 2005 Jun;5(6):1392-6 [15888046.001]
  • [Cites] Medicina (B Aires). 1998;58(1):58-60 [9674210.001]
  • [Cites] Haematologica. 2007 Apr;92(4):558-61 [17488669.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3053-7 [16254143.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):152-8 [3965933.001]
  • (PMID = 20140460.001).
  • [ISSN] 1432-198X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


50. Ballestrero A, Ferrando F, Miglino M, Clavio M, Gonella R, Garuti A, Grasso R, Ghio R, Balleari E, Gobbi M, Patrone F: Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma. Eur J Haematol; 2002 Feb;68(2):101-6
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.
  • BACKGROUND AND OBJECTIVES: High-dose chemotherapy (HDT) with autologous peripheral blood progenitor cell (PBPC) transplant has been increasingly used for newly diagnosed multiple myeloma (MM) in recent years.
  • Presently available results suggest an improvement in the complete remission rate and survival as compared to conventional chemotherapy.
  • However, there is no plateau in the survival curves, and experiments with new treatment schedules and conditioning regimens are warranted.
  • DESIGN AND METHODS: In a non-randomised controlled trial, 20 patients underwent three-step HDT following conventional vincristine/doxorubicin/dexamethasone (VAD)-based induction.
  • In the intensification phase patients received high-dose cyclophosphamide (HD-CY), high-dose etoposide (HD-VP), and mitoxantrone (NOV) plus melphalan (L-PAM) with haemopoietic rescue.
  • Maintenance treatment with interferon was given until relapse.
  • In five of the eight patients achieving complete remission (CR), the molecular disease was monitored by polymerase chain reaction technique (PCR).
  • RESULTS: Overall 18/20 (90%) patients responded, with a CR rate of 40%.
  • Monoclonal cells were detectable in the post-treatment bone marrow and in the aphereses of the five CR patients monitored by PCR.
  • Our results are in agreement with the hypothesis that HDT results in an increased remission rate and in prolonged survival in newly diagnosed MM, but a cure is unlikely.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Adult. Aged. Clone Cells / pathology. Combined Modality Therapy. Cyclophosphamide / administration & dosage. DNA, Neoplasm / analysis. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction / methods. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12038448.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan; VAD I protocol
  •  go-up   go-down


51. Tanaka PY, Pessoa VP Jr, Pracchia LF, Buccheri V, Chamone DA, Calore EE: Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma; 2007 Mar;7(5):364-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma among patients infected with HIV in post-HAART era.
  • BACKGROUND: Hodgkin lymphoma is considered a common type of non-AIDS defining tumor among patients infected with HIV, commonly presenting as a widespread disease and with different pathologic features compared with Hodgkin lymphoma in the general population.
  • Despite that, the best treatment option is undefined.
  • PATIENTS AND METHODS: The authors present a retrospective study of 31 patients with Hodgkin lymphoma-HIV attended at 3 Brazilian centers, 2 of them considered reference centers for HIV treatment.
  • Chemotherapy schemes used were ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) or hybrid MOPP-ABV (mechlorethamine/vincristine/procarbazine/prednisone-doxorubicin/bleomycin/vinblastine), with prophylactic granulocyte colony-stimulating factor.
  • RESULTS: Treatment response could be evaluated in 22 patients (70.9%) who completed initial treatment: 20 (91%) reached complete remission, 1 had partial remission, and 1 did not exhibit a response.
  • The overall response rate was 95.5% (95% confidence interval, 91.2%-99.8%).
  • After a median follow-up of 3 years, the overall survival (OS) rate among all patients was 80.3%; median OS was not reached.
  • On univariate analysis, only CD4 cell count at diagnosis was significantly related to survival.
  • CONCLUSION: This retrospective study shows that for patients with Hodgkin lymphoma development in the HIV setting in these 3 Brazilian centers, there was high complete remission and satisfactory OS rates, comparable with results found for Hodgkin lymphoma in patients without HIV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / statistics & numerical data. Bleomycin / administration & dosage. Brazil / epidemiology. Comorbidity. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage


52. Marino D, Burra P, Boccagni P, Calabrese F, Canova F, Trentin C, Boso C, Soldà C, Angeli P, Aversa SM: Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience. Anticancer Res; 2010 Jun;30(6):2383-91
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
  • Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after solid organ transplantation.
  • Reduction of immunosuppression (RI) is accepted as a first step treatment with a long-term complete response rate observed in 23-50% of patients.
  • Chemotherapy for diseases refractory to RI is based on small cohorts treated with different regimens.
  • The median time from transplantation to PTLD diagnosis was 5 years.
  • Seven monomorphic PTLD, 2 polymorphic and one Hodgkin disease were observed.
  • Epstein Barr virus was present in tumour tissue only in one case.
  • Initial therapy included RI in all patients.
  • Chemotherapy was used in eight patients.
  • No treatment-related mortality was observed and no patient developed graft rejection during chemotherapy.
  • At a median follow-up period of 25 months, 6 of the 10 patients were alive and without evidence of disease.
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Risk Factors. Rituximab. Survival Rate

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651397.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


53. Adani GL, Marcello D, Mazzetti J, Maestroni U, Anania G, Donini A: [Role of surgery in the treatment of primary gastric lymphoma and assessment of new therapeutic approaches]. G Chir; 2001 Aug-Sep;22(8-9):273-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of surgery in the treatment of primary gastric lymphoma and assessment of new therapeutic approaches].
  • [Transliterated title] Il ruolo della chirurgia nel trattamento dei linfomi gastrici primitivi e valutazione dei nuovi orientamenti terapeutici.
  • Controversy remains regarding the best treatment for primary gastric lymphoma (PGL).
  • Recent developments in diagnosis and chemotherapy have changed strategies for this disease.
  • Fourteen patients with primary gastric non-Hodgkin's lymphoma underwent surgery.
  • Before surgery 9/14 patients underwent Helicobacter pylori eradication, and 4/14 were treated with chemotherapy.
  • In two patients chemotherapy was not possible because of risk of perforation recurred.
  • Then patients underwent post-operative chemotherapy.
  • Involved-field radiation therapy was made in four patients.
  • Surgery was the treatment of choice in cases of gastric lymphoma non-responsive to medical therapy and to control complications or when gastroscopy did not supply correct diagnosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11682961.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


54. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D: A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Apr;37(3-4):351-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
  • The purpose of this study was to develop a model for predicting the occurrence of life-threatening neutropenia (LN, ANC < or = 0.5 x 10(9)/l) and febrile neutropenia (FN, an ANC < 0.5x10(9)/l in association with a body temperature of > or = 38.3 degrees C) after the first cycle of CHOP therapy in patients newly diagnosed with aggressive NHL.
  • One hundred and forty-five patients, aged > or = 15 years, with newly diagnosed diffuse mixed, diffuse large-cell or large-cell immunoblastic lymphoma (IWF categories, F, G, H), who had been treated with CHOP at King Chulalongkorn Memorial Hospital between June 1994 and December 1998, were entered into the study.
  • The criteria for eligibility included complete work-up for baseline evaluation, treatment with standard CHOP chemotherapy, at least one complete blood count performed during days 8-14 post-treatment or if at any time the patients experienced a BT of > or = 38.3 degrees C and were not treated with any colony-stimulating factors (CSFs).
  • Forty-eight percent of the patients were in stage III/IV, 36% had ECOG performance status (PS) II-IV, 30% had > or = 2 extranodal diseases, 59% had serum LDH > 1 x normal and 23% had bone marrow involvement.
  • The frequencies of patients in the low-, low-intermediate, high-intermediate and high risk groups according to the international index were 29%, 28%, 17% and 26%, respectively.
  • Thirty-nine percent of the patients had LN at nadir and 33% developed FN after the first course of CHOP.
  • By using stepwise logistic regression analysis, the pretreatment variables independently predictive of the LN at nadir and the FN were serum albumin concentration of < or = 3.5 g/dl, serum LDH > 1 x normal and whether there was bone marrow involvement of lymphoma at presentation.
  • The model, based on the incorporation of these three factors, identified three risk groups of patients with a predicted probability of developing LN at nadir of 81.5% (95% CI, 68.5-90.7) (high risk), 23.9% (95% CI, 12.6-38.8) (intermediate risk) and 4.4% (95% CI, 0.5-15.1) (low risk).
  • In conclusion, our model could be used as a means to identify patients with newly diagnosed aggressive NHL, treated with CHOP, who are at high risk (> or = 50% probability) of developing post-first course LN and FN, in whom CSF and/or antibiotic prophylaxis might be indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fever / epidemiology. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Prednisone / adverse effects. Prednisone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10752986.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


55. Végso G: [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility]. Magy Onkol; 2009 Jun;53(2):149-56
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility].
  • The increasing frequency of malignant tumors developing during chronic immunosuppression is an important determinant of the long-term survival of organ transplanted patients.
  • The increased tumor risk resulting from chronic renal failure, increasing age of prospective kidney recipients and, in addition, the increasing frequency of tumors diagnosed in the early post-transplantation period emphasize the importance of regular oncological screening of patients on the waiting list.
  • Early diagnosis and treatment of tumors and precancerous conditions are equally important in transplanted patients as well, and the tumor risk could be decreased by applying low dose immunosuppression and the preferential usage of immunosuppressive drugs with an oncologically favorable effect.
  • The prognosis of post-transplantation tumors is poor, as they respond poorly to therapy.
  • Lymphomas are of great importance because of their frequency.
  • Different immunosuppressive regimens represent varying degrees of risk in lymphoma development.
  • The composition of immunosuppression is a major factor in treatment; an oncologically ideal compound would prevent organ rejection and, at the same time, would not counteract oncological therapy.
  • We have shown that mycophenolic acid inhibits the proliferation of human B-cell non-Hodgkin lymphomas and induces apoptosis by activating the intrinsic pathway, both in vitro and in vivo.
  • The favorable properties of mycophenolic acid suggest that it can provide the necessary immunoprotection for the transplanted organ and, given its anti-lymphoma effects, it may also prove useful in the therapy of lymphoma patients.
  • It may also be helpful in the treatment of "traditional" lymphomas of the non-transplanted population, where the major cause of therapeutical failure is the development of apoptosis resistance.
  • Mycophenolic acid, combined with other chemotherapeutical drugs, may enhance apoptosis in lymphoma cells.
  • Our promising experimental results provide a basis for further, clinical studies.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Immunosuppressive Agents / adverse effects. Lymphoma / drug therapy. Lymphoma / immunology. Mycophenolic Acid / therapeutic use. Organ Transplantation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581181.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


56. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H: Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer; 2006 Jan 1;106(1):128-35
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
  • BACKGROUND: The authors sought to determine whether the availability of highly active antiretroviral therapy (HAART) coincided with changes in the epidemiology of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL).
  • By using the total number of patients with AIDS who were alive as of July 1 annually as the AIDS population denominator, the average annual incidence of NHL was estimated among patients with AIDS for the pre-HAART period (1988-1995) and post-HAART period (1996-2000).
  • The chi-square test was used to compare proportions, and a Cox proportional hazards model was used to compare survival between the pre-HAART and post-HAART periods.
  • RESULTS: The incidence of NHL decreased from 29.6 per 1000 person-years pre-HAART to 6.5 per 1000 person-years post-HAART.
  • The proportion of patients who had NHL of central nervous system (CNS) origin decreased from 28% pre-HAART to 17% post-HAART.
  • Among patients with systemic NHL, 54% received chemotherapy pre-HAART, and 72% received chemotherapy post-HAART.
  • The percentage of intermediate-grade NHL increased from 33% pre-HAART to 49% post-HAART, and the percentage of high-grade NHL decreased from 38% to 19%, respectively.
  • A diagnosis of human immunodeficiency virus infection preceding the NHL diagnosis and Stage IV NHL were associated with worse survival, whereas a diagnosis of NHL in the post-HAART period and chemotherapy were associated with better survival.
  • The median survival was 4 months pre-HAART and 9 months post-HAART.
  • CONCLUSIONS: Since the introduction of HAART, there has been a decrease in the incidence of systemic and CNS NHL among patients with AIDS.
  • Among patients with systemic, AIDS-related NHL, there has been decreased high-grade histology, increased use of chemotherapy, and improved survival.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Adult. Female. Humans. Incidence. Male. Registries. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16329140.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K07CA096480
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Terpos E, Theocharis S, Panitsas F, Philippidis T, Kotronis E, Karkantaris C: Autoimmune hemolytic anemia with myelodysplastic features followed by bilateral adrenal non-hodgkin lymphoma: a case report and review of the literature. Leuk Lymphoma; 2004 Nov;45(11):2333-8
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune hemolytic anemia with myelodysplastic features followed by bilateral adrenal non-hodgkin lymphoma: a case report and review of the literature.
  • Primary adrenal lymphoma is a rare entity characterized mainly by bilateral involvement, presenting predominantly diffuse large B-cell histology, adrenal insufficiency and poor prognosis.
  • We report here a case of a 77-year-old man who presented with autoimmune hemolytic anemia (AIHA), which preceded the diagnosis of lymphoma by more than 2 years.
  • An ultrasound guided biopsy revealed diffuse, large B-cell, lymphoma; subsequent staging revealed no other disease site, and the patient was considered to have primary adrenal lymphoma.
  • The patient had adrenal insufficiency at diagnosis.
  • He received hormonal replacement and chemotherapy, but he succumbed to his disease because of sepsis and multi-organ failure a few days post diagnosis.
  • To our knowledge, this is the first case in the literature in which AIHA preceded bilateral adrenal lymphoma.
  • We also provide a summary of the current data for the clinical features, diagnosis and treatment of primary adrenal lymphoma.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / pathology. Lymphoma, Non-Hodgkin / pathology. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Glands / pathology. Adrenal Insufficiency. Aged. Biopsy. Hormones / pharmacology. Humans. Lymphoma / immunology. Lymphoma / metabolism. Lymphoma, B-Cell / pathology. Male. Prognosis. Time Factors. Tomography, X-Ray Computed


58. Krishna RP, Lal R, Sikora SS, Yachha SK, Pal L: Unusual causes of extrahepatic biliary obstruction in children: a case series with review of literature. Pediatr Surg Int; 2008 Feb;24(2):183-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper highlights the etiology, diagnosis, management and outcome in nine unusual cases of extrahepatic biliary obstruction in children.
  • However, nine children (aged 1.5-15 years) presented with uncommon causes like (1) idiopathic benign non-traumatic inflammatory stricture (n = 3), (2) idiopathic fibrosing chronic pancreatitis (n = 2), (3) post-cholecystectomy type 4 benign biliary stricture (n = 1), (4) post-acute pancreatitis pseudo-cyst of pancreas (n = 1), (5) non-Hodgkin's lymphoma (NHL) with extramural common bile duct compression and gall bladder perforation (n = 1), and (6) Langerhan cell histiocytosis (LCH, n = 1).
  • The clinical features and the diagnostic work up of each group are discussed.
  • The patients with NHL and LCH were referred for chemotherapy after establishing tissue diagnosis at laparotomy.
  • With a follow-up period of 3 months to 7 years, seven children (with the exception of patients with NHL and LCH) are currently anicteric.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1995 Jun;130(6):597-602; discussion 602-4 [7763167.001]
  • [Cites] Ann Surg. 1985 Dec;202(6):720-4 [4073984.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1669-77 [8826926.001]
  • [Cites] Ann Surg. 1980 Jul;192(1):33-7 [7406561.001]
  • [Cites] J Pediatr Surg. 1995 Jun;30(6):777-80 [7666305.001]
  • [Cites] Am J Surg. 1983 Mar;145(3):343-8 [6837858.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1293-5 [12699969.001]
  • [Cites] JOP. 2006 May 09;7(3):262-73 [16685107.001]
  • [Cites] Ann Surg. 1989 May;209(5):532-8; discussion 538-40 [2705818.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):659-61 [4027545.001]
  • [Cites] Surgery. 1992 Nov;112(5):866-71 [1332203.001]
  • [Cites] J Pediatr Surg. 2006 Dec;41(12):1987-91 [17161188.001]
  • [Cites] Hepatogastroenterology. 1992 Aug;39(4):333-6 [1427579.001]
  • [Cites] J Pediatr Surg. 2005 Aug;40(8):1335-40 [16080944.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):849-52 [2765843.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):430-41 [10973393.001]
  • [Cites] J Pediatr Surg. 2006 Nov;41(11):1889-93 [17101365.001]
  • [Cites] Dig Dis Sci. 2002 Jun;47(6):1230-5 [12064796.001]
  • [Cites] Surgery. 2003 Sep;134(3):496-500 [14555939.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2063-5 [7942738.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):845-9 [12854111.001]
  • [Cites] J Am Coll Surg. 1995 Jan;180(1):101-25 [8000648.001]
  • [Cites] J Am Coll Surg. 2005 Dec;201(6):862-9 [16310689.001]
  • [Cites] Surgery. 2001 Jul;130(1):55-9 [11436012.001]
  • [Cites] Clin Radiol. 2003 Apr;58(4):269-78 [12662947.001]
  • [Cites] Gut. 1998 Nov;43(5):715-20 [9824357.001]
  • [Cites] Dig Surg. 2006;23(5-6):304-12 [17164542.001]
  • [Cites] J Pediatr Surg. 2001 Dec;36(12):1792-5 [11733908.001]
  • (PMID = 18071716.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


59. Akhtar S, El Weshi A, Abdelsalam M, Hussaini H, Janabi I, Rahal M, Maghfoor I: Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant; 2007 Oct;40(7):651-8
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
  • We report our experience with high-dose chemotherapy (HDC) and autologous SCT (ASCT) in 66 patients with primary refractory Hodgkin's lymphoma (PR-HL) who received salvage chemotherapy followed by BEAM as HDC.
  • Before salvage chemotherapy, stages I:II:III:IV were 2:21:14:29, bulky disease 27%, involvement of mediastinum 79%, spleen 26% and extranodal site 47%, 92% had ESHAP as salvage.
  • Post-ASCT evaluation showed response in 50 patients (76%); complete response (CR) 37 (56%), partial response 14 (21%), no response or stable disease 3 (5%) and progressive disease in 10 (15%).
  • Another five patients achieved CR after radiation therapy and one after surgery, making total CR 43 (65%).
  • From diagnosis and HDC, median follow-up is 38.5 and 22.8 months and median overall survival (OS) 78 and 57 months, respectively.
  • Twenty-two patients (33%) died due to disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Child. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Multivariate Analysis. Neoplasm Staging. Podophyllotoxin / administration & dosage. Prognosis. Retrospective Studies. Salvage Therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660837.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


60. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most of the previous publications used old pathologic classifications and old diagnostic and treatment approaches.
  • OBJECTIVE: To examine the clinical presentation, pathologic classification, treatment and outcome of patients with NHL of the colon.
  • METHODS: A retrospective study was performed of all patients with NHL and involvement of the colon in two medical centers.
  • The patient group consisted of 17 patients over a 13 year period.
  • Most patients had bulky disease: three had a diameter >5 cm and eight a diameter >10 cm.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • CONCLUSIONS: Most colonic lymphomas are aggressive B cell lymphomas.
  • Diagnosis is often delayed.
  • Early diagnosis may prevent perforation.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Registries. Remission Induction. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


61. Rifkind J, Mollee P, Messner HA, Lipton JH: Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look? Leuk Lymphoma; 2005 Feb;46(2):217-23
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?
  • Mantle cell lymphoma is a subtype of non-Hodgkin's lymphoma.
  • Mantle cell is generally considered incurable with a median overall survival of about 3 years.
  • It is most common in 50 - 70 year old individuals and for this reason transplantation is not a common therapeutic option.
  • Autologous stem cell transplantation does not appear to improve survival with most patients relapsing after transplant and no disease-free plateau.
  • We present 6 mantle cell patients that had a mean of 3 different types of therapy prior to allogeneic transplantation.
  • Allogeneic transplantation is associated with substantial mortality post-transplant from acute toxicity and GVHD.
  • Despite the extensive amount of pretransplant therapy in our patient population, there was no transplant related mortality.
  • Survival from the date of diagnosis is a median of 6.5 plus years.
  • The results of this series would suggest that in a selected group of patients allogeneic stem cell transplantation may be the treatment of choice for lymphomas not curable by standard therapy or autotransplant.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Mantle-Cell / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Graft Survival. Graft vs Host Disease / drug therapy. Humans. Male. Middle Aged. Remission Induction / methods. Retrospective Studies. Survival Rate. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621804.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. Lazar AD, Shpilberg O, Shaklai M, Bairey O: Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma. Isr Med Assoc J; 2009 Jan;11(1):16-22
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
  • BACKGROUND: There is currently no standard salvage chemotherapy for the 40-50% of patients with non-Hodgkin's lymphoma who fail first-line treatment.
  • OBJECTIVES: To review the experience of a major tertiary medical center with DVIP (dexamethasone, etoposide, ifosfamide and cisplatin) salvage therapy for primary refractory/relapsing NHL.
  • METHODS: We reviewed the records of all patients with NHL who received DVIP salvage therapy during the period 1993 to 2005.
  • RESULTS: We identified 37 adult patients (mean age 56.3 years): 29 with aggressive lymphoma and 8 with indolent lymphoma.
  • Mean event-free survival was 13.5 months (range 0-82 months), mean time between diagnosis and DVIP treatment 18.5 months (range 2-101), and mean number of DVIP cycles 1.9.
  • Consolidation with stem cell transplantation was used in 14 patients with aggressive lymphoma and 4 with indolent lymphoma; 14 patients, all with aggressive lymphoma, responded (12 complete, 2 partial).
  • Five year overall survival since the diagnosis for the whole sample was 39.4 +/- 8.7%, and 5 year post-DVIP overall survival 37.6 +/- 8.0%.
  • On multivariate analysis, SCT was the strongest predictor of survival (relative risk 0.73, P < 0.0001) followed by a high score on the International Prognostic Index (RR 3.71, P = 0.032).
  • CONCLUSIONS: DVIP salvage therapy for NHL was associated with a low response rate of 35% but a 5 year post-DVIP survival rate of 37.6%.
  • Patients who are refractory to salvage treatment with DVIP might still be salvaged with SCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Dexamethasone / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. Stem Cell Transplantation. Survival Analysis. Treatment Failure

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344007.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; DICE protocol
  •  go-up   go-down


63. Robotin MC, Law MG, Milliken S, Goldstein D, Garsia RJ, Dolan GM, Kaldor JM, Grulich AE: Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med; 2004 Sep;5(5):377-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
  • OBJECTIVES: To analyse clinical features and predictors of survival for AIDS-related non-Hodgkin's lymphoma (NHL) in the era of highly active antiretroviral therapy (HAART), compared to earlier in the HIV epidemic.
  • METHODS: All AIDS-NHL cases diagnosed at three inner Sydney hospitals caring for people with AIDS during 1985-2001 were identified through medical record searches.
  • Demographic, clinical, immunological and histopathological information was recorded.
  • Year of NHL diagnosis was grouped into three periods, corresponding to whether monotherapy (1985-1991), dual therapy (1992-1995) or HAART (1996-2001) was the main treatment for HIV infection.
  • Statistical comparisons were made between the pre-HAART and post-HAART eras.
  • Divergent trends were identified for systemic and primary central nervous system (CNS) NHL.
  • For systemic NHL, the CD4 count at NHL diagnosis increased markedly to 208 cells/microL in the post-HAART era (P=0.014) and there was a trend towards presentation as the first AIDS-defining illness (69%, P=0.053), and as earlier stage NHL disease (42%, P=0.048).
  • Median survival time increased from 4.2 months in 1985-1991 to 19 months in the post-HAART era (P<0.001).
  • In a multivariate model, predictors of poor survival from systemic NHL included: NHL diagnosis after another AIDS-defining illness (P<0.001), stage 4 NHL (P<0.001), presentation at extra lymphatic sites (P=0.001), and nonreceipt of chemotherapy (P=0.002).
  • After adjusting for the factors, those diagnosed in the era of HAART had a significant 56% reduction in rate of death (P<0.001).
  • In contrast, for CNS NHL, clinical features were little changed and survival did not improve in the era of HAART.
  • CONCLUSIONS: Systemic NHL is presenting earlier in the course of HIV disease, and at a less advanced NHL stage.
  • In contrast, primary CNS NHL remains a disease which presents late in the course of HIV infection and is associated with a very poor prognosis.
  • [MeSH-major] Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Australia. Central Nervous System Neoplasms / mortality. Disease Outbreaks. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15369514.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


64. Sparano JA: Human immunodeficiency virus associated lymphoma. Curr Opin Oncol; 2003 Sep;15(5):372-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus associated lymphoma.
  • PURPOSE OF REVIEW: Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of systemic nonHodgkin lymphoma, Hodgkin disease, and primary central nervous lymphoma (PCNSL).
  • The purpose of this review is to highlight recent advances in the diagnosis and management of lymphoma occurring in patients with HIV infection.
  • RECENT FINDINGS: Lymphoma occurring in patients with HIV infection has been associated with a very poor prognosis.
  • Recently reported studies have provided new information regarding the influence of highly active antiretroviral therapy (HAART) on the development and clinical presentation of lymphoma, the feasibility of combining HAART with standard chemotherapy, the molecular classification of lymphoma, the role of rituximab in the management of lymphoma, and the use of novel treatment strategies for the treatment of Hodgkin disease.
  • SUMMARY: The improved prognosis for patients with HIV-associated lymphoma in the post-HAART era indicates that therapeutic interventions may be potentially curative, and represent a shift away from therapeutic nihilism and reduced-intensity treatment approaches that have been employed in the recent past.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Stem Cell Transplantation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12960519.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


65. Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, Pettengell R, Milligan D, Morris EC, Goldstone AH, Linch DC, Mackinnon S: Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant; 2008 May;41(9):765-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation.
  • This study compares outcome of reduced-intensity conditioned transplant (RIT) with outcome of conventional non-transplant therapy in patients with Hodgkin's lymphoma relapsing following autograft.
  • There were 72 patients in two groups who had relapsed, and received salvage therapy with chemotherapy+/-radiotherapy.
  • The second group-historical controls (n=34), relapsing before the advent of RIT-had no further high-dose therapy.
  • This group was required to respond to salvage therapy and live for over 12 months post-relapse, demonstrating potential eligibility for RIT, had this been available.
  • Overall survival (OS) from diagnosis was superior following RIT (48% at 10 years versus 15%; P=0.0014), as was survival from autograft (65% at 5 years versus 15%; P< or =0.0001).
  • Responses were seen in 8 of 15 patients receiving donor lymphocyte infusions (DLI) for relapse/progression, with durable remission in five patients at median follow-up from DLI of 45 months (28-55).
  • These data demonstrate the potential efficacy of RIT in heavily pre-treated patients whose outlook with conventional therapy is dismal, and provide evidence of a clinically relevant graft-versus-lymphoma effect.
  • [MeSH-major] Graft vs Tumor Effect. Hodgkin Disease / mortality. Hodgkin Disease / prevention & control. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195684.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ: The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant; 2007 Apr;13(4):486-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
  • Autologous hematopoietic stem cell transplantation (auto HSCT) has become the standard treatment for patients with relapsed diffuse large-cell non-Hodgkin's lymphoma (NHL) responding to conventional salvage chemotherapy.
  • This study was undertaken to determine whether the International Prognostic Index (IPI) assessed at time of relapse (IPI-R) could be used to identify patients with greater probability for long-term survival following auto HSCT.
  • Eighty patients, median age 47 years (range 19-68 years), with diffuse large cell lymphoma in either second complete remission (CR 2, n = 27) or partial remission (PR 2, n = 53) were treated between 1984 and 2002 with auto HSCT.
  • Clinical features predictive of overall survival (OS) and progression-free survival (PFS) were analyzed.
  • Post-auto HSCT, CR was achieved in 73 patients (91%).
  • With a median follow-up of 5 years (range 1.0-14.2 years), OS and PFS at 5 years were 38% (95% confidence interval [CI] 27%-50%) and 32% (95% CI 22%-42%), respectively.
  • The high-risk group (3, 4, or 5 IPI factors) had 2.0 times (95% CI 1.1-4.0, P = .03) the risk of death and 2.2 times (95% CI 1.2-4.0, P = .01) the risk of relapse as the low-risk group (0, 1, or 2 IPI factors).
  • In Cox regression analysis, high-risk IPI-R status (relative risk [RR] 2.4, 95% CI 1.2-4.8, P = .02) and bone marrow (BM) involvement at diagnosis (RR 2.9, 95% CI 1.3-6.4, P = .01) were independent predictors for poor OS.
  • Similarly, high-risk IPI-R status (RR 2.5, 95% CI 1.3-4.7, P = .01) and BM involvement at diagnosis (RR 3.9, 95% CI 1.7-8.7, P = .001) were independent predictors for poor PFS.
  • These results suggest that the IPI-R predicts OS and PFS following auto HSCT for patients with aggressive NHL in CR 2 or PR 2.
  • Patients with high-risk IPI-R should be considered for novel therapeutic approaches.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Severity of Illness Index. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382255.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Cheng T, Forsyth P, Chaudhry A, Morris D, Glück S, Russell JA, Stewart DA: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant; 2003 Apr;31(8):679-85
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
  • Treatment of primary central nervous system lymphoma (PCNSL) with combined high-dose methotrexate (HD-MTX)-based chemotherapy and whole-brain radiotherapy (WBRT) is associated with severe neurotoxicity, but high relapse rates are associated with the use of either modality alone.
  • In an attempt to improve upon these dismal results, we treated seven PCNSL patients with HD-MTX-based induction therapy followed by thiotepa, busulfan, cyclophosphamide (TBC), and autologous stem cell transplant (ASCT), without WBRT.
  • Six of these patients had at least one of the following poor prognostic features: Karnofsky performance status (KPS) <or=50%, age >60 years, or relapsed disease.
  • All but one patient tolerated the treatment well and experienced improvements in neurological function and overall performance status post-transplant.
  • No treatment-induced neurotoxicity (dementia, ataxia, and incontinence) was observed although the follow-up is short.
  • One early treatment-related death occurred in a patient with multiple comorbid medical conditions.
  • Five patients are currently alive and relapse-free at 5, 8, 24, 36, and 42 months from diagnosis.
  • One additional patient relapsed and died 33 months after diagnosis.
  • Two of the seven patients received TBC/ASCT as the only treatment after disease progression following their initial chemotherapy and both remain relapse-free at the time of this report, 22 and 31 months post-TBC/ASCT.
  • In conclusion, prolonged CR can be attained after chemotherapy-only treatment of poor prognosis PCNSL.
  • Furthermore, this small series suggests that high-dose chemotherapy for PCNSL should include drugs that penetrate the CNS such as busulfan and thiotepa rather than standard lymphoma regimens such as BEAM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Brain / pathology. Brain Neoplasms / radiotherapy. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prognosis. Radiotherapy / adverse effects. Thiotepa / administration & dosage. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692608.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


68. Clark AD, Douglas KW, Mitchell LD, McQuaker IG, Parker AN, Tansey PJ, Franklin IM, Cook G: Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment. Br J Haematol; 2002 Jun;117(3):605-12
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
  • A phase I-II study of high-dose (HD) alkylating agents in newly diagnosed patients with multiple myeloma after maximum response to Z-Dex (idarubicin, dexamethasone) therapy and DHAP (cisplatin, HD cytosine arabinoside, dexamethasone), stem cell mobilization is reported.
  • Twenty-six patients, median age 56 years (range 42-66), completed Z-Dex chemotherapy and peripheral blood stem cells (PBSC) were mobilized with DHAP.
  • Patients then preceded to cyclophosphamide (HD Cy: 6 g/m(2)) with granulocyte colony-stimulating factor followed by busulphan-melphalan-conditioned PBSC autograft.
  • Interferon alpha was introduced at 3 months post transplant as maintenance therapy.
  • Median time from diagnosis to transplantation was 8 months (range 6-12).
  • Mean CD34+ cell dose collected was 15.8 x 10(6)/kg (CI 11.8, 19.8).
  • Median time from DHAP to HD-Cy was 6 weeks (range 4-12) and from HD-Cy to transplant was 8 weeks (range 6-12).
  • On an intent-to-treat basis, the response rates were three complete response (CR, 12%), 21 partial response (PR, 80%) and two stable disease (SD, 8%) post Z-Dex, five CR (19%) and 21 PR (81%) post HD-Cy, and 14 CR (54%) and 12 PR (46%) post transplant.
  • The treatment-related mortality (TRM) was 4% (1 patient).
  • Median overall survival (OS) and progression-free survival (PFS) have not been reached; estimated values were 60 and 48 months respectively.
  • DHAP produces effective PBSC mobilization and sequential HD therapy, including autologous PBSCT, in patients who received Z-Dex; this offers significant durable disease response rates with acceptable TRM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Multiple Myeloma / drug therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Interferon-alpha / administration & dosage. Male. Melphalan / administration & dosage. Middle Aged. Recombinant Proteins. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol 2002 Sep;118(4):1201
  • (PMID = 12028028.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; 99210-65-8 / interferon alfa-2b; G1LN9045DK / Busulfan; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan; ZRP63D75JW / Idarubicin; DHAP protocol
  •  go-up   go-down


69. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M: Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma; 2008 Jul;49(7):1329-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
  • Primary mediastinal large B-cell lymphoma (PMLCL) is an aggressive non-Hodgkin lymphoma with distinct clinical and gene expression profiles.
  • Outcomes of salvage chemotherapy and autologous stem cell transplantation (ASCT) for relapsed or refractory disease (RR) have not been well characterised.
  • We retrospectively identified 180 consecutive RR patients (37 PMLCL and a control group of 143 DLBCL) that underwent salvage chemotherapy.
  • The overall response rate (ORR) to salvage chemotherapy (25% vs. 48%, p = 0.01) and 2-year OS after diagnosis of RR disease (15% vs. 34%, p = 0.018) was inferior in PMLCL patients.
  • The 2-year post-ASCT OS (67% PMLCL vs. 53%, p = 0.78) and PFS (57% PMLCL vs. 36%, p = 0.64) were similar.
  • RR PMLCL had an inferior ORR and survival compared with DLBCL but chemosensitive PMLCL and DLBCL patients have similar outcomes post-ASCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Mediastinal Neoplasms / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604722.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A: Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev; 2008 Jan-Mar;10(1):25-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
  • The objective of this study is to systematically review the epidemiology and the clinical and virologic aspects of multicentric Castleman's disease in HIV-positive patients and to evaluate treatment strategies and outcome, especially in relation to HAART administration.
  • The authors have conducted a systematic review of the English literature for all cases of newly diagnosed multicentric Castleman's disease in HIV-positive patients.
  • The 25 studies which met the selection criteria included 84 HIV-positive patients with multicentric Castleman's disease (20 pre-HAART and 64 post-HAART era).
  • Of them, the majority (90%) were men with 33 months median time from detection of HIV-positivity to multicentric Castleman's disease diagnosis in the HAART era.
  • Kaposi's sarcoma was present in 72% of the patients and respiratory system involvement in 34%.
  • Of the 48 patients on HAART, 64% were already on HAART at multicentric Castleman's disease diagnosis, having a better immunologic profile and a lower incidence of Kaposi's sarcoma than the 35% of patients who initiated HAART after multicentric Castleman's disease diagnosis.
  • Nevertheless, the two groups did not have significantly different mortality rates (30 vs. 38%).
  • At multicentric Castleman's disease diagnosis, a wide range of CD4 counts was recorded, suggesting that disease presentation could occur at any CD4 count.
  • With regard to treatment, the study confirmed the high rates of response with rituximab (anti-CD20 monoclonal).
  • Polychemotherapy with CHOP has given long-term remission in a subset of patients.
  • Other regimens used in the treatment of HIV-related multicentric Castleman's disease were antiviral agents, immunomodulatory agents, and thalidomide.
  • The fatality rate among HIV-related multicentric Castleman's disease cases reviewed was 44%, significantly lower than that of HIV-negative individuals (65%), while median survival of the latter was 29 months longer than that of HIV-infected individuals.
  • Infection, multiorgan failure, Kaposi's sarcoma, non-Hodgkin lymphoma and progressive multicentric Castleman's disease were the most often reported causes of death.
  • In conclusion, multicentric Castleman's disease is a lymphoproliferative disorder with an increasing prevalence in HIV-infected individuals.
  • Even though life expectancy in multicentric Castleman's disease seems to have significantly improved in the HAART era, it remains a disease with a poor prognosis and an increased incidence of non-Hodgkin lymphoma in the HIV-context.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Giant Lymph Node Hyperplasia / complications. HIV Infections / complications
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Humans


71. Zhang YN, Zheng YY, Zhou XG, Zhang SH, Jin Y, Xie JL, Chen SY, Shi Y, Wu LH: [Clinicopathologic study of splenic marginal zone B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Apr;38(4):243-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of splenic marginal zone B-cell lymphoma].
  • OBJECTIVE: To study the clinicopathologic features, diagnosis and differential diagnosis of splenic marginal zone B-cell lymphoma (SMZL).
  • METHODS: The clinical data, histologic findings and immunophenotype of 8 SMZL cases were studied.
  • Post-operative fludarabine-based chemotherapy was given to 3 patients, two of them achieved complete remission and 1 case died during the course of chemotherapy.
  • The average survival time was 21.5 months (range: 6 to 60 months).
  • Six of them exhibited the classic biphasic appearance with central aggregates of small B cells rimmed by a peripheral zone of atypical monocytoid B cells.
  • There was infiltration of tumor cells in the red pulp, sheets in appearance in all 8 cases.
  • The proliferation index, as highlighted by Ki-67 immunostaining, was low (< 15%).
  • CONCLUSIONS: SMZL is an indolent B-cell non-Hodgkin lymphoma.
  • The main clinical manifestations are splenomegaly and abnormalities in blood counts.
  • The main modality of treatment is splenectomy.
  • Adjuvant fludarabine-based chemotherapy helps to achieve complete remission.
  • In general, the prognosis of this lymphoma type is good.
  • The lymphoma cells predominantly grow in micronodular pattern, with atypical monocytoid B cells rimming around the small B cells, which aggregates in the center.
  • The differential diagnosis includes other small B-cell lymphomas and lymphoid hyperplasia of spleen.
  • [MeSH-major] Antigens, CD20 / metabolism. Lymphoma, B-Cell, Marginal Zone / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunophenotyping. Ki-67 Antigen / metabolism. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Spleen / pathology. Splenectomy. Survival Rate

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575895.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


72. Burns DS, Azzouz F, Sledge R, Rutledge C, Hincher K, Monahan PO, Cripe LD: Music imagery for adults with acute leukemia in protective environments: a feasibility study. Support Care Cancer; 2008 May;16(5):507-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Music imagery for adults with acute leukemia in protective environments: a feasibility study.
  • BACKGROUND: Patients receiving intensive chemotherapy can experience increased distressed related to both the cancer diagnosis and treatment isolation.
  • If not addressed, distress can lead to anxiety, depression, and post-traumatic stress disorder.
  • The purpose of this study was to determine the feasibility and possible benefits of a music imagery intervention for patients hospitalized in a protective environment for the treatment of acute leukemia or high-grade non-Hodgkin's lymphoma.
  • MATERIALS AND METHODS: Adults receiving intensive myelosuppressive chemotherapy in a protective environment were randomized to standard care or standard care plus music imagery.
  • Both groups improved over time on all outcomes (all p < 0.001).
  • However, a subgroup of individuals with low baseline negative affect who received the intervention reported significantly less anxiety at discharge than individuals with low baseline negative affect who did not receive the intervention.
  • [MeSH-major] Anxiety / psychology. Imagery (Psychotherapy). Leukemia / psychology. Lymphoma, Non-Hodgkin / psychology. Music Therapy
  • [MeSH-minor] Acute Disease. Adult. Affect. Aged. Fatigue. Feasibility Studies. Female. Hematologic Neoplasms. Humans. Male. Middle Aged. Relaxation Therapy. Severity of Illness Index. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Music Ther. 2001 Spring;38(1):51-65 [11407965.001]
  • [Cites] Psychooncology. 2005 Aug;14(8):607-17 [15651053.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2723-9 [14669295.001]
  • [Cites] J Music Ther. 2001 Fall;38(3):193-211 [11570932.001]
  • [Cites] J Psychosom Res. 2003 Apr;54(4):289-92 [12670604.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):43-6 [9671330.001]
  • [Cites] J Music Ther. 2005 Fall;42(3):185-99 [16086604.001]
  • [Cites] J Music Ther. 2004 Fall;41(3):192-214 [15327345.001]
  • [Cites] Health Psychol. 1995 Mar;14(2):101-8 [7789344.001]
  • [Cites] Cancer. 1997 Nov 15;80(10):1936-44 [9366296.001]
  • [Cites] Pain Manag Nurs. 2003 Sep;4(3):112-23 [14566709.001]
  • [Cites] J Adv Nurs. 1997 Jan;25(1):68-78 [9004013.001]
  • [Cites] Leukemia. 1998 Apr;12(4):586-92 [9557618.001]
  • [Cites] Psychooncology. 1999 Jan-Feb;8(1):64-73 [10202784.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(1):77-83 [15502851.001]
  • [Cites] J Adv Nurs. 1999 Aug;30(2):439-47 [10457247.001]
  • [Cites] Health Psychol. 1997 Jul;16(4):390-400 [9237092.001]
  • [Cites] Bone Marrow Transplant. 2000 Feb;25(3):315-8 [10673704.001]
  • [Cites] Semin Oncol Nurs. 1995 Nov;11(4):279-88 [8578036.001]
  • [Cites] J Pers Soc Psychol. 1988 Jun;54(6):1063-70 [3397865.001]
  • (PMID = 17891547.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / 5F32AT001144-02
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


73. Choquet S, Mamzer BM, Hermine O, Porcher R, Nguyen QS, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V, Leblond V: Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res; 2002;159:67-80
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of prognostic factors in post-transplant lymphoproliferative disorders.
  • Organ transplantations can lead to post-transplant lymphoproliferative disorders (PT-LPDs) as a result of immunosuppressive therapy.
  • PT-LPDs clearly differ from non-Hodgkin's lymphomas occurring in immunocompetent patients, in terms of clinical presentation, pathological findings and treatment response.
  • We studied 61 patients from two transplant centers who developed a PT-LPD after kidney (34 patients), heart (19 patients), lung (4 patients) or liver (3 patients) transplantation.
  • Treatment consisted of modification of the immunosuppressive regimen, chemotherapy and/or monoclonal antibody infusions.
  • Analyzing potential prognostic factors, we found that factors predictive of failure to achieve a complete remission were, in univariate analysis, a performance status (PS) > or =2 and negativity of the tumor for the Epstein-Barr virus (EBV), and in multivariate analysis, only the PS.
  • Factors predictive of lower survival were, in univariate analysis, a PS > or =2, number of sites > 1, primary central nervous system (CNS) location, T-cell phenotype, monoclonality of the tumor, tumor negativity for EBV and chemotherapy as a first treatment; in multivariate analysis, only PS and the number of sites were statistically significant.
  • The International Prognostic Index (IPI) failed to identify a patient subgroup with a lower survival or treatment response, whereas a simple index using PS and number of sites clearly identified three different groups.
  • The median survival has not yet been reached in the lower-risk group, whereas it is 34 months in the intermediate-risk patients and 1 month in the high-risk group.
  • [MeSH-major] Lymphoproliferative Disorders / diagnosis. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785846.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


74. Stefan DC, Stones D: How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma; 2009 Feb;50(2):196-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How much does it cost to treat children with Hodgkin lymphoma in Africa?
  • Hodgkin lymphoma (HL) is a common B-cell childhood neoplasm and it has a higher incidence in the 0-14 year age group in developing countries compared to developed countries.
  • Treatment achieves a cure rate of about 80%.
  • In African countries with a small gross domestic product per capita the cost of treating HL in children may be prohibitive.
  • To determine the direct costs of treatment of HL in South Africa and to propose a more cost-effective approach to investigation and treatment for children diagnosed with HL in Africa, tumor registry data for 138 children with HL from two South African hospitals were analysed retrospectively.
  • The cost of treatment for stage 2 disease was calculated, including investigations and chemotherapy.
  • The analysis included the cost of a follow-up period of 2 years.
  • The total cost of diagnosing, staging, treating with chemotherapy and following up a child with stage 2 HL for 2 years post-therapy was ZAR 53178.20 = USD 6647.27 = EUR 4431.51.
  • Follow-up expenditure was much higher than initial chemotherapy costs.
  • The major factors driving the cost for the whole group of 138 patients were as follows: stage, radiologic imaging, radiotherapy, second-line chemotherapy, hospitalisation and febrile neutropenia.
  • The total cost of treatment of HL is affordable for first world countries, but it remains expensive for developing countries, especially in Africa where the GDP is often under USD 2000 per head.
  • Early diagnosis, use of less toxic protocols such as ABVD, close monitoring to prevent complications and elimination of unnecessary tests and investigations may reduce the overall cost.
  • [MeSH-major] Hodgkin Disease / economics. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Africa / epidemiology. Child. Child, Preschool. Female. Humans. Male. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Feb;50(2):152-3 [19235011.001]
  • (PMID = 19197725.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Svane IM, Nikolajsen K, Johnsen HE: Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. Scand J Immunol; 2007 Oct;66(4):465-75
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
  • The present study analyses the influence of high-dose chemotherapy (HD) and autologous stem cell transplantation on natural and vaccine induced specific immunity in multiple myeloma patients.
  • Peripheral blood was collected from six multiple myeloma (MM) patients at serial time points in connection with treatment and during a follow-up period of 3 months.
  • At diagnosis and prior to induction chemotherapy TNFalpha expressing T cells in 5/6 patients were found specific for CMV, 3/6 for VZV and 4/6 for TT.
  • Serial analyses during treatment conclude impaired immune response, however, 3 months post-transplantation all but one patient had regained cytokine expressing CD8(+) T cells specific for CMV, VZV and TT.
  • A striking observation was the low cytokine reactivity (close to zero) measured in G-CSF mobilized blood at the time of leukapheresis.
  • In spite of a general reduction of the CD4/CD8 ratio following transplantation, recovery of antigen specific CD4(+) T cells reactivity generally occurred prior to CD8(+) recovery and often to a higher level.
  • In conclusion, the study demonstrates that natural as well as vaccine induced specific immunity present prior to HD was regained after stem cell transplantation, hence identifying a possible window for future vaccination trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cancer Vaccines / immunology. Hematopoietic Stem Cell Transplantation. Multiple Myeloma / immunology. Multiple Myeloma / therapy
  • [MeSH-minor] CD4-CD8 Ratio. Combined Modality Therapy. Cytokines / analysis. Cytokines / immunology. Cytomegalovirus / immunology. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Flow Cytometry. Granulocyte Colony-Stimulating Factor / immunology. Herpesvirus 3, Human / immunology. Humans. T-Lymphocyte Subsets / drug effects. T-Lymphocyte Subsets / immunology. Tetanus Toxoid / immunology. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850592.001).
  • [ISSN] 0300-9475
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / Tetanus Toxoid; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  •  go-up   go-down


76. Dhakal S, Biswas T, Liesveld JL, Friedberg JW, Phillips GL, Constine LS: Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):188-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma.
  • PURPOSE: To evaluate the patterns and timing of initial recurrence in patients with Hodgkin's lymphoma (HL) who subsequently underwent high-dose chemotherapy with autologous stem cell transplantation to enhance our understanding of the natural history of this disease and its modern treatment strategies and to direct approaches to disease surveillance.
  • METHODS AND MATERIALS: The records of 69 patients with HL who had undergone high-dose chemotherapy with autologous stem cell transplantation in our center between May 1992 and June 2006 were analyzed.
  • The initial diagnosis had been made between April 1982 and January 2005 at a median patient age of 33 years (range, 19-65).
  • RESULTS: Early-stage HL patients developed a relapse at a median of 2.1 years (range, 0.5-10.3), with 91% of relapses at the initial disease site, 71% of which (65% overall) were only in previously involved sites.
  • Advanced-stage HL patients developed a relapse at a median of 1.5 years (range, 0.6-10.5), with 97% at the initial site, 71% of which (69% overall) were only in previously involved sites.
  • Single-site relapses occurred in 47% of early- vs. 26% of advanced-stage patients, and extranodal relapses occurred in 12% of early- vs. 31% of advanced-stage patients.
  • CONCLUSIONS: Almost all patients with HL who develop relapse and subsequently undergo high-dose chemotherapy with autologous stem cell transplantation initially developed recurrence in previously involved disease sites.
  • Early-stage HL relapses often occurred in single sites, and advanced-stage disease relapses were more likely in multiple and extranodal sites.
  • The interval to recurrence was brief, suggesting that the frequency of screening should be the greatest in the early post-therapy years.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / drug therapy. Hodgkin Disease / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250770.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Glez-Chamorro A, Jimenez C, Moreno-Glez E, Glez-Pinto I, Loinaz C, Gomez R, Garcia I, Alonso O, Palma F, Grande C: Management and outcome of liver recipients with post-transplant lymphoproliferative disease. Hepatogastroenterology; 2000 Jan-Feb;47(31):211-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
  • BACKGROUND/AIMS: The possibility of development of post-transplant lymphoproliferative disease by patients receiving immunosuppressive therapy is well known.
  • However, elective treatment and outcome remain controversial.
  • We reviewed the management and outcome of our patients with post-transplant lymphoproliferative disease.
  • Patients who developed post-transplant lymphoproliferative disease were reviewed retrospectively.
  • Incidence, clinical presentation, risk factors and outcomes were examined with special emphasis on ductopenic rejection and hilum involvement.
  • RESULTS: Eleven patients developed a post-transplant lymphoproliferative disease (2.4%).
  • These were B-cell non-Hodgkins lymphoma, Epstein-Barr virus-associated in all cases.
  • Seven patients (63.6%) developed a lymphoproliferative disease before 9 months post-transplant and 4 recipients (36.4%) after 20 months.
  • No late lymphomas regressed after withdrawal from immunosuppression.
  • Six patients (54.5%) were treated with chemotherapy.
  • Eight patients (72.7%) had a tumoral remission.
  • Five patients (45.5%) developed chronic rejection after immunosuppressant discontinuation.
  • CONCLUSIONS: Patients with post-transplant lymphoproliferative disease require a close follow-up in order to promptly treat conditions that could lead to death.
  • In our series, these were more closely associated with a failing transplanted organ than with the lymphoma itself.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Liver Transplantation. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Drug Therapy, Combination. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / etiology. Epstein-Barr Virus Infections / therapy. Female. Graft Rejection / prevention & control. Humans. Incidence. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Retrospective Studies. Risk Factors. Treatment Outcome


78. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol; 2009 Jul 10;27(20):3354-62
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
  • PURPOSE: We studied the incidence, risk factors, treatment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD) that occurred at the University of Michigan since 1964.
  • PATIENTS AND METHODS: We identified 7,040 patients who received solid organ transplantation (SOT) and post-transplantation immunosuppressive therapy.
  • Seventy-eight patients developed PTLD.
  • RESULTS: Diffuse large B-cell lymphoma (n = 43), polymorphic PTLD (n = 10), Hodgkin's lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tissue lymphoma (n = 3) were all over-represented in the SOT population compared with a population sample from the Surveillance, Epidemiology, and End Results (SEER) database; follicular lymphoma (n = 0) was underrepresented.
  • Available histologic analysis of tumor tissue showed that 75% were CD20 positive and that 62% were EBV positive; EBV-positive tumors occurred sooner after SOT than EBV-negative tumors (mean, 29 v 66 months).
  • Extralymphatic disease (79%), poor performance status (68%), elevated lactate dehydrogenase (LDH; 71%), and advanced stage (68%) disease were all common at the time of lymphoma diagnosis.
  • Two thirds of patients had a complete response when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone-like chemotherapy (either with or without rituximab).
  • CONCLUSION: EBV-naïve patients who receive a donor organ from an EBV-infected donor are in the highest-risk situation for PTLD development.
  • Most of these lymphomas are CD20 positive.
  • Follicular lymphoma is unusual.
  • With treatment, survival of patients with PTLD was indistinguishable from that of the SEER population sample.
  • [MeSH-major] Lymphoma / etiology. Lymphoproliferative Disorders / etiology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / metabolism. Humans. Immunohistochemistry. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. In Situ Hybridization. Kaplan-Meier Estimate. Male. Michigan. Middle Aged. RNA, Viral / genetics. Risk Factors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use. Treatment Outcome. Viral Matrix Proteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Immunosuppressive Agents; 0 / RNA, Viral; 0 / Viral Matrix Proteins; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


79. Semionov V, Shvartzman P: Post herpetic itching--a treatment dilemma. Clin J Pain; 2008 May;24(4):366-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post herpetic itching--a treatment dilemma.
  • METHODS: We report on a 22-year-old male patient with a history of non-Hodgkin lymphoma, chronic renal failure peritoneal dialysis dependent, presented with a disabling pruritus around his left eye and forehead.
  • Two months before, he was diagnosed with herpes zoster ophtalmicus.
  • His itching intensity was 10/10 on a visual analog scale and he reported no pain.
  • RESULTS: Our patient suffered of PHI who responded successfully to a combination of antihistamine and an antiepileptic agent.
  • DISCUSSION: The mechanism of postherpetic neuralgia and PHI are not well understood and no single best treatment for postherpetic neuralgia and PHI is known.
  • Clinical experience suggested that neuropathic itch may be more resistant to treatment than neuropathic pain.
  • This immunocompromized patient with a severe disabling PHI responded to antihistaminic and anticonvulsant treatment.
  • [MeSH-major] Anticonvulsants / therapeutic use. Herpes Zoster Ophthalmicus / complications. Histamine H1 Antagonists / therapeutic use. Neuralgia, Postherpetic / drug therapy. Neuralgia, Postherpetic / etiology

  • MedlinePlus Health Information. consumer health - Shingles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18427235.001).
  • [ISSN] 0749-8047
  • [Journal-full-title] The Clinical journal of pain
  • [ISO-abbreviation] Clin J Pain
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Histamine H1 Antagonists
  •  go-up   go-down


80. Merli F, Bertini M, Luminari S, Mozzana R, Bertè R, Trottini M, Stelitano C, Botto B, Pizzuti M, Quintana G, De Paoli A, Federico M, Intergruppo Italiano Linfomi: Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica; 2004 Aug;89(8):973-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
  • BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate quality of life (QOL) in a group of elderly patients (> 65 years) with aggressive non-Hodgkin's lymphoma (NHL) treated with chemotherapy regimens containing anthracyclines.
  • DESIGN AND METHODS: QOL was evaluated in a population of elderly patients with aggressive NHL enrolled in a phase III clinical trial run by the Intergruppo Italiano Linfomi (IIL) from 1996 to 1999 to compare two different anthracycline-containing regimens (mini-CEOP vs P-VEBEC).
  • The EORTC-QLQ-C30 questionnaire, which has already been validated in oncology, was used.
  • The questionnaire was administered at the time of diagnosis, half way through the chemotherapy and at the time of restaging.
  • RESULTS: Ninety-one patients completed pre-therapy and post-therapy questionnaires and they are the subject of this report.
  • Baseline QOL assessment showed a strong correlation of poor values of QOL with anemia and high risk according to the International Prognostic Index (IPI).
  • At the end of treatment no functional scales showed worse values.
  • INTERPRETATION AND CONCLUSIONS: The EORTC-QLQ-C30 is feasible even in a population of elderly patients, in whom it had never been tested before.
  • The improvement of QOL at the end of the treatment demonstrated that the symptoms of the disease have a greater negative influence on the patient's life than do the side effects of the therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / physiopathology. Quality of Life
  • [MeSH-minor] Aged. Anthracyclines / administration & dosage. Appetite. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Neoplasm Staging. Pain. Prednisone / administration & dosage. Sleep. Surveys and Questionnaires. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15339681.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anthracyclines; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1; P-VEBEC protocol
  •  go-up   go-down


81. Tichelli A, Bhatia S, Socié G: Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol; 2008 Jul;142(1):11-26
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haematopoietic stem cell transplantation (HCT) is the treatment of choice for defined malignant and non-malignant haematological disorders.
  • The main drawbacks of HCT are early transplant-related mortality and late complications, which interfere with patient outcome, health status and quality of life.
  • In comparison with other post-transplant complications, cardiac or cardiovascular consequences seem to occur at a much lower frequency.
  • Early complications are usually associated with patient history before transplantation, primary diagnosis, age of the patient and associated comorbidities, and the type of transplantation and conditioning used.
  • Late cardiac and cardiovascular events may occur years and even decades after HCT, and are related to cardiotoxic chemotherapy, mediastinal radiation therapy, gender, age at transplantation, cardiovascular risk factors and graft-versus-host disease in allogeneic HCT.
  • As has been observed in long-term survivors of Hodgkin lymphoma, where the incidence of cardiovascular complications emerged as a significant problem with increasing follow-up, it is anticipated that the incidence of these complications after HCT will also increase significantly with increasing follow-up of the survivors.
  • [MeSH-major] Cardiovascular Diseases / etiology. Hematopoietic Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Age Factors. Amyloidosis / etiology. Anthracyclines / adverse effects. Graft vs Host Disease / etiology. Heart Diseases / etiology. Heart Diseases / prevention & control. Hematopoietic Stem Cell Mobilization / adverse effects. Humans. Radiotherapy / adverse effects. Risk Factors. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430191.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 30206
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines
  • [Number-of-references] 130
  •  go-up   go-down


82. Bamgbola OF, Kaskel F: Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol; 2005 Nov;20(11):1622-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis.
  • Unlike iron therapy, folate use is not a standard of care in hemodialysis (HD) patients.
  • Despite iron repletion, poor response to erythropoietin (EPO) treatment is common.
  • Theoretical evidence for folate deficiency (FD) includes chronic blood loss, inflammation, malnutrition, and nutrient loss during dialysis.
  • Due to poor diagnostic standards, early studies failed to establish a role for FD in EPO resistance.
  • Given that hematological response to therapeutic intervention is the gold standard for FD, its diagnosis was therefore based on composite scoring of RBC and/or folate indices.
  • Fifteen subjects (8-20 years) on chronic HD were enrolled in this study.
  • Thereafter, 5-mg folic acid was administered orally after HD sessions over a six-month period.
  • Folate indices before and after treatment were compared using percentage differences and paired t-tests.
  • In contrast to previous studies, 26.7% of study subjects met the criteria for FD.
  • Furthermore, the substantial (post-folate) reduction in the EPO requirement validates the need for therapeutic intervention, and therefore the presence of functional FD in the population.
  • [MeSH-major] Anemia, Iron-Deficiency / drug therapy. Erythropoietin / therapeutic use. Folic Acid Deficiency / complications. Kidney Failure, Chronic / complications. Renal Dialysis
  • [MeSH-minor] Adolescent. Adult. Child. Drug Resistance. Female. Folic Acid / blood. Folic Acid / therapeutic use. Hemoglobins / analysis. Humans. Male. Recombinant Proteins. Vitamin B 12 / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J R Coll Physicians Lond. 1997 May-Jun;31(3):291-5 [9192331.001]
  • [Cites] Nephrol Dial Transplant. 1999 Feb;14(2):366-8 [10069190.001]
  • [Cites] Perit Dial Int. 2003 Mar-Apr;23(2):111-5 [12713075.001]
  • [Cites] Clin Ther. 2003 Jun;25(6):1786-805 [12860499.001]
  • [Cites] Blood Purif. 2002;20(4):349-56 [12169844.001]
  • [Cites] Clin Nephrol. 1999 Oct;52(4):239-45 [10543326.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):121-6 [12866382.001]
  • [Cites] Ann Intern Med. 1989 Dec 15;111(12):992-1000 [2688507.001]
  • [Cites] J Nephrol. 2001 Jan-Feb;14(1):32-5 [11281342.001]
  • [Cites] Lancet. 2002 Jan 19;359(9302):248-52 [11812579.001]
  • [Cites] Am J Kidney Dis. 2001 Sep;38(3):510-7 [11532682.001]
  • [Cites] J Pediatr. 2001 May;138(5):710-4 [11343048.001]
  • [Cites] J Ren Nutr. 2000 Oct;10(4):196-201 [11070147.001]
  • [Cites] Clin Nutr. 2003 Feb;22(1):53-8 [12553950.001]
  • [Cites] Clin Lab Haematol. 2001 Feb;23(1):15-20 [11422225.001]
  • [Cites] Pediatr Nephrol. 2001 Oct;16(10):805-11 [11605787.001]
  • [Cites] J Am Soc Nephrol. 2003 May;14(5):1314-9 [12707400.001]
  • [Cites] Am J Clin Nutr. 1975 Nov;28(11):1217-22 [1190101.001]
  • [Cites] J Am Soc Nephrol. 2001 Nov;12(11):2465-73 [11675424.001]
  • [Cites] Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S182-238 [11229970.001]
  • [Cites] Soc Sci Med. 1992 May;34(9):983-91 [1631611.001]
  • [Cites] Am J Kidney Dis. 1995 Apr;25(4):548-54 [7702049.001]
  • [Cites] Arch Intern Med. 1976 Jul;136(7):756-60 [938164.001]
  • [Cites] Nephrol Dial Transplant. 2002;17 Suppl 5:2-7 [12091599.001]
  • [Cites] Clin Nephrol. 2000 Jan;53(1):48-54 [10661482.001]
  • [Cites] Am J Med Sci. 2000 Jun;319(6):343-52 [10875288.001]
  • [Cites] Am J Kidney Dis. 1991 Jul;18(1):50-9 [2063855.001]
  • [Cites] Am J Nephrol. 2004 May-Jun;24(3):289-95 [15087588.001]
  • [Cites] Pediatr Nephrol. 2002 Jul;17(7):511-4 [12172764.001]
  • [Cites] Am J Kidney Dis. 2001 Dec;38(6):1251-63 [11728958.001]
  • [Cites] J Am Soc Nephrol. 2000 Mar;11(3):530-8 [10703677.001]
  • [Cites] J Am Soc Nephrol. 2003 Jul;14(7):1776-84 [12819237.001]
  • [Cites] Acta Med Austriaca. 2002;29(2):57-60 [12050947.001]
  • [Cites] J Nutr. 2003 Dec;133(12):4107-11 [14652356.001]
  • [Cites] Am J Kidney Dis. 1999 Mar;33(3):492-7 [10070913.001]
  • (PMID = 16133045.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 9-526-3740
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


83. Santoe MF, Van Houten AA, Muller AF, Berghout A: [A pregnant woman with autoimmune thyroiditis and recurrent goiter]. Ned Tijdschr Geneeskd; 2004 Jul 17;148(29):1455-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Een zwangere met auto-immuunthyreoïditis en recidiverend struma.
  • Thyroid-suppression therapy with levothyroxine resulted in regression of the goitre.
  • At the age of 26 there was a transitory recurrence of the goitre during a pregnancy, during which time the thyroid peroxidase antibodies became strongly positive.
  • Six months post partum the goitre recurred again, accompanied by pain in the throat and fever.
  • Serology established the diagnosis of viral thyroiditis due to a Coxsackie-B virus.
  • The size of the goitre decreased after treatment with acetylsalicylic acid and prednisone.
  • Histology revealed a non-Hodgkin lymphoma of the type diffuse large B-cell (stage II), very likely a primary thyroid lymphoma.
  • The lymphoma was refractory to cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP); this was followed by intensive chemotherapy and autologous stem-cell transplantation, resulting finally in a complete remission.
  • Primary thyroid lymphoma is a rare disease, but autoimmune thyroiditis appears to be an important predisposing factor.
  • [MeSH-major] Goiter / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Thyroid Neoplasms / diagnosis. Thyroiditis, Autoimmune / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / analysis. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Iodide Peroxidase / immunology. Prednisone / administration & dosage. Pregnancy. Recurrence. Stem Cell Transplantation. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15326651.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.11.1.8 / Iodide Peroxidase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


84. Stern M, Herrmann R, Rochlitz C, Dirnhofer S, Pless M: A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma. Eur J Haematol; 2005 Mar;74(3):267-70
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma.
  • Classical Hodgkin lymphoma (HL) is a rare complication after solid organ transplantation.
  • We describe the first case of a patient developing CD20-positive HL after renal transplantation treated with the monoclonal antibody rituximab.
  • Treatment with single agent rituximab led to partial remission.
  • Subsequent combined modality treatment consisting of chemotherapy (adriamycin, bleomycin, vindesin and dacarbacin), immunotherapy (rituximab) and involved field irradiation achieved complete remission.
  • Different therapeutic strategies in the treatment of patients developing lymphoproliferative disease - and particularly HL - after solid organ transplantation are discussed.
  • [MeSH-major] Hodgkin Disease / therapy. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20. Combined Modality Therapy. Diagnosis, Differential. Herpesvirus 4, Human. Humans. Male. Rituximab


85. Simon Z, Ress Z, Toldi J, Trauninger A, Miltényi Z, Illés A: Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility? Int J Hematol; 2009 May;89(4):523-8
MedlinePlus Health Information. consumer health - Myasthenia Gravis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility?
  • With Hodgkin lymphoma (HL), other (autoimmune) diseases may occasionally occur or associate, whereas as a late treatment-complication, second tumour may develop.
  • In our patient HL was diagnosed in 1996 and consequently received COPP/ABV and mantle irradiation.
  • In 2000 Graves's disease, in 2001 myasthenia gravis was diagnosed, which showed resistance for immunosuppressant drugs, thus plasmapheresis, intravenous immunoglobulin treatments were applied.
  • In 2005, the residual mediastinal tumour started progressive growth, which leads to thoracotomy in which the tumour was removed, it was malignant peripheral nerve sheath tumour.
  • The disease showed progression despite the chemotherapy applied and the patient died in 2007 due to respiratory failure.
  • Not even the postmortem histopathologic examination revealed the relapse of HL.
  • Association of Hodgkin lymphoma, and two antibody-mediated autoimmune diseases, Graves' disease and myasthenia gravis, is rare and has not yet been reported in the literature.
  • The etiologic role of genetic predisposition and immune regulatory disorder must definitely be thought of, as the possibility of mere coincidence is extremely small.
  • Malignant peripheral nerve sheath tumour is a rare complication of irradiation, which underlines the importance of the risk or/and response adapted therapy of HL.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Graves Disease / complications. Hodgkin Disease / complications. Myasthenia Gravis / complications. Neurofibrosarcoma / radiotherapy
  • [MeSH-minor] Adult. Autopsy. Fatal Outcome. Female. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed


86. Cicognani A, Cacciari E, Pasini A, Burnelli R, De Iasio R, Pirazzoli P, Paolucci G: Low serum inhibin B levels as a marker of testicular damage after treatment for a childhood malignancy. Eur J Pediatr; 2000 Jan-Feb;159(1-2):103-7
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low serum inhibin B levels as a marker of testicular damage after treatment for a childhood malignancy.
  • The aim of this study was to evaluate the role of inhibin B and the determination of its concentration to diagnose testicular damage after treatment for a childhood malignancy.
  • Thirty-seven males treated for Hodgkin disease (n = 11) or non-Hodgkin lymphoma (n = 26) were examined at a mean age of 16.9+/-2.9 years.
  • Mean age at the stop of therapy was 11.3+/-3.0 years and in most cases the chemotherapy regimen included gonadal damaging alkylating agents.
  • In post-pubertal patients (i.e., over 16 years) a positive correlation was found between testicular size and inhibin level (r = 0.53, P<0.05), but not between testicular size and testosterone level.
  • Pathological low levels (values that differed by more than 2 SD from the mean value of control subjects) were found in 20 patients for inhibin B and 8 for testosterone (P<0.01) and pathological high values in 19 patients for FSH and 3 for LH.
  • CONCLUSION: This study confirms the role that inhibin B plays in the regulation of FSH secretion and provides further evidence of the utility of its evaluation as a direct indicator of male gonadal dysfunction.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Hodgkin Disease / drug therapy. Inhibins / blood. Lymphoma, Non-Hodgkin / drug therapy. Testis / drug effects. Testis / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653341.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers; 3XMK78S47O / Testosterone; 57285-09-3 / Inhibins; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


87. Bodet-Milin C, Kraeber-Bodéré F, Dupas B, Morschhauser F, Gastinne T, Le Gouill S, Campion L, Harousseau JL, Wegener WA, Goldenberg DM, Huglo D: Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica; 2008 Mar;93(3):390-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
  • BACKGROUND: The study aimed to evaluate FDG-PET imaging for early prediction of response to radioimmunotherapy in patients with non-Hodgkin's lymphoma.
  • They also underwent assessment by conventional diagnostic methods that included chemotherapy at baseline and six weeks post-radioimmunotherapy, and every three months until progression.
  • Responses evaluated from conventional methods were classified using International Workshop Response Criteria as complete response, unconfirmed CR, partial response, stable disease, or progression of disease.
  • FDG-PET images were evaluated visually and were classified as complete response, partial response or progression of disease.
  • RESULTS: A total of 81 paired imaging studies were obtained post-radioimmunotherapy (including 3 patients after retreatment) and evaluated as complete response (n=34), partial response (n=24) or progression of disease (n=23) by FDG-PET, and complete response (n=12), unconfirmed complete response (n=31), partial response (n=15), stable disease (n=8) or progression of disease (n=15) by conventional methods.
  • Of the 31 responses evaluated as unconfirmed complete response by conventional methods, 20 (65%) were classified as negative for disease (complete response) by PET while the other 11 (35%) were positive for disease (7 partial response and 4 progression of disease).
  • Among 22 assessable PET images acquired at six weeks post-radioimmunotherapy, the mean time-to-progression was 15.6 months when PET was negative for disease (complete response), compared with 5.4 months when PET was positive (partial response or progression of disease) (p=0.008).
  • Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET six weeks after radioimmunotherapy were 86%, 63%, 80%, 71% and 77% respectively, compared with 36%, 87%, 83%, 44% and 55% respectively using conventional methods.
  • CONCLUSIONS: A positive assessment of disease by PET acquired six weeks after radioimmunotherapy corresponded with a shorter time to progression.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Positron-Emission Tomography. Radioimmunotherapy / methods. Radiopharmaceuticals / therapeutic use. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / immunology. Disease Progression. Female. Fluorine Radioisotopes / therapeutic use. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Salvage Therapy. Sensitivity and Specificity. Sialic Acid Binding Ig-like Lectin 2 / immunology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268287.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / CD22 protein, human; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Yttrium Radioisotopes; 0 / epratuzumab; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


88. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Ileum was the most commonly involved site (8 of 14 patients, 57.1%), followed by jejunum (2 of 14 patients, 14.3%) and duodenum (1 of 14 patients, 7.1%).
  • Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients.
  • Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS).
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Ab Hamid S, Wastie ML: Primary non-Hodgkin's lymphoma presenting as a uterine cervical mass. Singapore Med J; 2008 Mar;49(3):e73-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma presenting as a uterine cervical mass.
  • We report a 43-year-old woman who presented with post-coital bleeding.
  • Pelvic examination revealed a uterine cervical mass, which confirmed to be large B cell lymphoma on histopathological examination.
  • Computed tomography showed a primary lesion in the uterine cervix with no lymph node or other extranodal involvement.
  • The patient responded to CHOP (cyclophosphamide, adriamycin, vincristine and prednisolone) chemotherapy regime with no major side effects.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage


90. Ahamed SM, Varma RS, Mathew T, Hamide A, Badhe BA: Spontaneous tumour lysis syndrome associated with non-Hodgkin's lymphoma--a case report. Indian J Pathol Microbiol; 2006 Jan;49(1):26-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous tumour lysis syndrome associated with non-Hodgkin's lymphoma--a case report.
  • Spontaneous tumour lysis syndrome is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, metabolic acidosis and hypocalcemia, that occur even prior to the treatment of a neoplasm.
  • This rare occurrence was encountered in a patient with non-Hodgkin's lymphoma (NHL), of follicular cell type.
  • Conservative but intensive treatment led to complete resolution.
  • Subsequent chemotherapy was well tolerated.
  • [MeSH-major] Lymphoma, Follicular / complications. Tumor Lysis Syndrome / diagnosis. Tumor Lysis Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625969.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Phosphates
  •  go-up   go-down


91. Mounier N, Spina M, Spano JP: Hodgkin lymphoma in HIV positive patients. Curr HIV Res; 2010 Mar;8(2):141-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma in HIV positive patients.
  • Hodgkin lymphoma (HL) represents one of the most common types of a non-AIDS-defining tumour that occurs in the HIV population, and its incidence is increasing in the post Highly Active Anti-retroviral Therapy (HAART) era.
  • Despite the aggressiveness of that disease, the outcome of patients with HIV-HL has improved with better, combined antineoplastic and antiretroviral approaches.
  • New and effective antiretroviral drugs, in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HL with chemotherapy.
  • The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HL may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival.
  • In addition, new functional imaging tools, like the Positron Emission Tomography (PET), may help to guide treatment and minimize long term toxicity.
  • [MeSH-major] HIV Infections / complications. Hodgkin Disease / complications. Hodgkin Disease / epidemiology
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Humans. Positron-Emission Tomography. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163350.001).
  • [ISSN] 1873-4251
  • [Journal-full-title] Current HIV research
  • [ISO-abbreviation] Curr. HIV Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


92. ASADA D, MATSUBARA H, KATO I, OSADA K, URYU K, TOKUMASU M, UMEDA K, WATANABE K, ADACHI S, OKAMOTO S, UEMOTO S, NAKAHATA T: Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy. Rinsho Ketsueki; 2009 Nov;50(11):1607-11
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy.
  • High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.
  • We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.
  • At day 833 after the transplantation, he was diagnosed with PTLD (post-transplantation lymphoproliferative disorder, Burkitt-type malignant lymphoma).
  • During induction therapy, he suffered ileal perforation and ileostomy was performed.
  • Subsequent HD-MTX therapy caused acute renal failure that required continuous hemodialysis.
  • After recovery of his renal function, we could safely treat the patient with HD-MTX therapy by controlling drainage from ileostoma with total parenteral nutrition.
  • [MeSH-minor] Biliary Atresia / surgery. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / etiology. Child, Preschool. Drainage. Humans. Hypovolemia / etiology. Intestinal Perforation / etiology. Intestinal Perforation / surgery. Liver Transplantation. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / etiology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009434.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


93. Isam H, Al-Wahadneh A: Successful Bone Marrow Transplantation in a Child with X-Linked Hyper-IgM Syndrome. Saudi J Kidney Dis Transpl; 2004 Oct-Dec;15(4):489-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful Bone Marrow Transplantation in a Child with X-Linked Hyper-IgM Syndrome.
  • A 13-year-old boy was diagnosed at the age of three years as having hyper IgM Immunodeficiency syndrome (HIgM).
  • It is a rare congenital disease characterized by recurrent infections and very low level of serum immunoglobulin (IgG, IgA) and elevated IgM.
  • Conservative treatment with antibiotics and regular intravenous immunoglobulin (IVIG) was not satisfactory.
  • At the age of five, the patient developed Hodgkin's lymphoma, which was treated successfully with chemotherapy.
  • Experience with Bone Marrow Transplantation (BMT) in such cases is limited as a definitive treatment for this kind of syndromes.
  • He was transplanted from his HLA-matched sister, and three years post BMT follow-up he showed good clinical recovery and immunoreconstitution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642786.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


94. Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M, Tokyo Children's Cancer Study Group: Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatr Blood Cancer; 2007 Aug;49(2):127-32
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
  • BACKGROUND: Various methods of intensive chemotherapy have contributed to an improved survival in pediatric acute myeloid leukemia (AML).
  • We here report the long-term results of the two consecutive trials of Tokyo Children's Cancer Study Group (TCCSG), incorporating repetitive use of high-dose cytarabine (HD-Ara-C) based combination chemotherapy in post-remission phase.
  • PROCEDURE: A total of 216 eligible children with newly diagnosed AML were treated in the two consecutive multi-center trials of TCCSG, M91-13 and M96-14, from August 1991 to September 1998.
  • In M91-13 trial, patients received eight courses of intensive post-remission chemotherapy, including six HD-Ara-C containing courses, after remission-induction therapy.
  • Autologous hematopoietic stem cell transplantation (HSCT) could be selected by physician's choice, and allogeneic HSCT was allocated if donor was available.
  • In M96-14 trial, the last two HD-Ara-C courses were omitted from the chemotherapy arm.
  • RESULTS: The remission-induction rate was 88.8% and probability of 5-year Overall survival (OS) and event-free survival (EFS) were 62% (56-69% with 95% Confidence intervals (CIs)) and 56% (49-62%), respectively.
  • Treatment-related mortality (TRM) was 7.8%.
  • Among patients without Down syndrome (DS) or acute promyelocytic leukemia (APL), the presence of t(8;21) or inv(16) was a significant good prognostic factor both in the univariate and multivariate analyses.
  • CONCLUSIONS: These results suggest that repetitive use of HD-Ara-C was effective and safe for childhood AML.
  • However, further optimization of AML therapy is required.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Disease-Free Survival. Down Syndrome / complications. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Hydrocortisone / administration & dosage. Infant. Infection / etiology. Infection / mortality. Japan / epidemiology. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Mitoxantrone / administration & dosage. Remission Induction. Survival Analysis. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome. Tretinoin / administration & dosage. Vincristine / administration & dosage


95. Roque J, Rios G, Humeres R, Volpi C, Herrera JM, Schultz M, Rios H, Rius M, Salgado C, Hepp J: Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Transplant Proc; 2006 Apr;38(3):930-1
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
  • Among 23 pediatric patients who underwent orthotopic liver transplant (OLT), we report two (11 and 26 months old) with posttransplant lymphoproliferative disease (PTLD) that occurred in the early posttransplantation period.
  • The patients should progression to a Burkitt's and a non-Hodgkin's lymphoma that appeared 3 months posttransplantation.
  • One patient experienced acute graft rejection, which resolved with steroids and low doses of tacrolimus, she is free of disease at 24 months after the end of treatment.
  • The other patient relapsed with a cerebral lymphoma, receiving aggressive chemotherapy, but died due to sepsis.
  • In conclusion, PTLD occurred among in 2/23 patients who underwent OLT and appeared in the first quarter post OLT.
  • The risk factors associated with early PTLD were primary EBV infection after OLT, young age, and EBV-negative recipient receiving a transplant from an EBV-positive donor.
  • Antiviral treatment alone was inefficient; withdrawal of immunosuppression and courses of Rituximab and cyclophosphamide were well tolerated and controlled PTLD.
  • One patient died.
  • [MeSH-minor] Biliary Atresia / surgery. Burkitt Lymphoma / diagnosis. Child, Preschool. Disease Progression. Epstein-Barr Virus Infections / diagnosis. Fatal Outcome. Female. Humans. Infant. Lymphoma / diagnosis. Postoperative Period. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647513.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Di Cosimo S, Ferretti G, Partenzi A, Manicone AM, D'Aprile M: Gastric stump lymphoma five years after distal gastrectomy. Leuk Lymphoma; 2003 Feb;44(2):365-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric stump lymphoma five years after distal gastrectomy.
  • We report the case of a 77-year-old man who developed low grade B cell non-Hodgkin's lymphoma of the gastric stump 5 years after undergoing a distal gastrectomy for benign gastric ulcer.
  • Lymphoma occurring in the post-operative stomach would appear to be very rare, with only 14 previously recorded cases.
  • The median period of lymphoma onset after ulcer surgery is about 20 years (range 9-43 years) and gastric remnants of lymphoma are generally diagnosed in low stage, when surgery is possible and makes the prognosis good.
  • The clinical case presented herein is quite different from the others.
  • The patient developed lymphoma within 5 years of the ulcer surgery, thus, earlier than generally reported in literature; he presented with massive regional and extra-regional nodes involvement and liver metastases and he poorly responded to antiblastic chemotherapy.
  • The pathogenetic role of Helicobacter pylori (HP) infection and the possibility of malignant lymphoma developing in the gastric stump are discussed.
  • [MeSH-major] Gastrectomy / adverse effects. Lymphoma, B-Cell / etiology. Stomach Neoplasms / etiology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Stomach Ulcer / complications. Stomach Ulcer / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12688360.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


97. Koczka CP, Goodman AJ: Gastric amyloidoma in patient after remission of Non-Hodgkin's Lymphoma. World J Gastrointest Oncol; 2009 Oct 15;1(1):93-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric amyloidoma in patient after remission of Non-Hodgkin's Lymphoma.
  • Amyloidosis is commonly systemic, occasionally organ-limited, and rarely a solitary localized mass.
  • The latter, commonly referred to as tumoral amyloidosis, is described as occurring in nearly every organ/tissue.
  • We describe a 72 year-old black male from Barbados presenting with 3 d of diffuse abdominal pain.
  • His medical history included Non-Hodgkin's Lymphoma diagnosed five years ago, status-post six rounds of cyclophosphamide, adriamycin, vincristine, prednisone chemotherapy, and currently was in remission.
  • On computed tomography scan of the abdomen, thickening and calcification of the gastric wall was noted along with pneumatosis.
  • A large non-bleeding 3 cm polyp was also seen in post bulbar area of duodenum.
  • Biopsies were stained with Congo red and gave green birefringence under polarized light, consistent with tumoral amyloidosis.
  • Positron emission tomography scan revealed diffuse gastric mucosa uptake compatible with gastric malignancy without metastatic foci.
  • Treatment for gastric amyloidomas has presently been one of observation or, at most, resection of the amyloid mass.
  • It is not known if our patient required the same approach or if this warranted the re-institution of chemotherapy for Non-Hodgkin's Lymphoma.
  • Until more reports of tumoral amyloidosis are made known, treatment as well as prognosis remain uncertain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160781.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999100
  • [Keywords] NOTNLM ; Amyloidoma / Duodenum / Lymphoma / Non-Hodgkin / Stomach
  •  go-up   go-down


98. Heise W: GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):57-69
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GI-lymphomas in immunosuppressed patients (organ transplantation; HIV).
  • Gastrointestinal lymphoma plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl.
  • HIV, transplantation, immunosuppression following chemotherapy, or inflammatory bowel disease).
  • Lymphoma in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses.
  • While gastrointestinal lymphoma in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of lymphoma.
  • In HIV-associated non-Hodgkin's lymphoma, gastrointestinal lesions as the most frequent extranodal localisation occur in 30-50% of lymphoma patients, are late events of HIV infection with severe immunosuppression and are mainly diagnosed with advanced disease stages Ann Arbour III or IV.
  • With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in AIDS, a decrease of AIDS-related GI lymphoma was noted with improved survival rates and prognosis of lymphoma.
  • Therapy strategies including chemotherapy, immunotherapy and HAART will show promising results in response and survival rates.
  • [MeSH-major] Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymphoma / immunology. Lymphoma, AIDS-Related / immunology. Organ Transplantation
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Endoscopy, Gastrointestinal. Humans. Immunotherapy / methods. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206109.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 84
  •  go-up   go-down


99. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood; 2000 Aug 15;96(4):1259-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
  • CD20-targeted radioimmunotherapy is a promising new treatment for B-cell non-Hodgkin lymphoma (NHL).
  • We now provide updated and long-term data on 59 chemotherapy-relapsed/refractory patients treated with iodine (131)I tositumomab in a phase I/II single-center study.
  • Fifty-three patients received individualized therapeutic doses, delivering a specified total-body radiation dose (TBD) based on the clearance rate of a preceding dosimetric dose.
  • Six patients received dosimetric doses only.
  • Dose-escalations of TBD were conducted separately in patients who had or had not undergone a prior autologous stem cell transplant (ASCT) until a nonmyeloablative maximally tolerated TBD was established (non-ASCT = 75 cGy, post-ASCT = 45 cGy).
  • Fourteen additional non-ASCT patients were treated with 75 cGy.
  • Unlabeled antibody was given prior to labeled dosimetric and therapeutic doses to improve biodistribution.
  • Thirty-five (83%) of 42 with low-grade or transformed NHL responded versus 7 (41%) of 17 with de novo intermediate-grade NHL (P =.005).
  • Reversible hematologic toxicity was dose limiting.
  • Long-term, 5 patients developed elevated thyroid-stimulating hormone levels, 5 were diagnosed with myelodysplasia and 3 with solid tumors.
  • A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL. (Blood.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / immunology. Antigens, CD20 / immunology. Female. Follow-Up Studies. Humans. Iodine Radioisotopes / administration & dosage. Male. Middle Aged. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10942366.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR-00042; United States / NCI NIH HHS / CA / P01-CA-42678; United States / NCI NIH HHS / CA / R01-CA56794
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Iodine Radioisotopes
  •  go-up   go-down


100. Juweid ME: Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2006;:259-65, 510-1
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma.
  • Use of positron emission tomography (PET) or PET/ computed tomography (CT) in Hodgkin lymphoma (HL) continues to expand worldwide.
  • PET is currently widely utilized for response assessment after completion of therapy and, to a lesser extent, for pretreatment staging and assessment of response during therapy (therapy monitoring).
  • In pretreatment staging, PET cannot replace CT or bone marrow biopsy (BMB); however, it can provide complementary information to both CT and BMB, potentially resulting in a modification of disease stage (usually upstaging) in about 15-20% of patients with impact on management in about 5-15%.
  • PET for response assessment at the conclusion of treatment is substantially more accurate than CT because of its ability to distinguish between viable tumor and necrosis or fibrosis in posttherapy residual mass (es) that are present in about two-thirds of patients with HL without any other clinical or biochemical evidence of disease.
  • The role of PET for therapy monitoring is still evolving but may prove to be the most exciting with potentially high impact on patient management and outcome.
  • PET evaluation during therapy appears to be at least as accurate for predicting patient outcome as evaluation after completion of therapy and its use is clearly justified if the purpose is to provide an early and yet accurate assessment of response with the clear intent of tailoring therapy according to the information provided by the scan.
  • The role of PET scanning for post-therapy surveillance without clinical, biochemical or radiographic evidence of disease remains controversial, primarily because of the potential for a disproportionate fraction of false-positive findings, potentially resulting in increasing cost without proven benefit from earlier PET detection of disease compared to standard surveillance methods.
  • Large prospective studies are therefore needed to determine whether routine surveillance by PET is both cost-effective and whether it results in meaningful changes in patient management and/or outcome.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124070.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down






Advertisement